2021-11-12T16:58:13-06:00 2020-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2020-01-01 911157127 PATH PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 KELLY PRIESTLEY CONTROLLER 2062853500 2021-11-12 1 KELLY PRIESTLEY 999009999 RICHARD J LOCASTRO CPA P00288314 3019519090 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z KELLY PRIESTLEY 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 357796602 0 X WWW.PATH.ORG X 1981 WA SEE PART III, LINE 1. 15 15 714 0 0 0 286808545 287454383 2038 0 6723428 12502251 836870 1030112 294370881 300986746 55619080 67994827 0 0 131590498 132096396 0 0 2409886 105099261 92968260 292308839 293059483 2062042 7927263 243064155 283556203 204045574 234982056 39018581 48574147 X PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O) 0 0 115045810 20527002 GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; AND NONCOMMUNICABLE DISEASES. THE DIVISION ALSO OVERSEES PATH'S WORK IN HEALTH SYSTEMS INNOVATION AND DELIVERY, AND MANAGES OUR COUNTRY OFFICES.(CONTINUED ON SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASESPATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM INCLUDES MORE THAN 100 PATH STAFF MEMBERS IN MORE THAN TEN COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. PATH-PIONEERED APPROACHES HAVE CONTRIBUTED TO REMARKABLE PROGRESS IN MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2020, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. MACEPA'S WORK INCLUDED EVALUATING THE LATEST, MOST SENSITIVE DIAGNOSTIC TESTS; ESTABLISHING RAPID REPORTING SYSTEMS; AND CONTINUING TO SUPPORT POPULATION-WIDE, DRUG-BASED STRATEGIES SUCH AS MASS DRUG ADMINISTRATION. WITH A NEW GRANT FROM THE BILL & MELINDA GATES FOUNDATION, MACEPA BEGAN IDENTIFYING OPPORTUNITIES IN ADDITIONAL HIGH-MALARIA-BURDEN GEOGRAPHIES SUCH AS THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), MALAWI, MALI, AND NIGERIA.PATH WAS ALSO AWARDED AN ADD-ON TO OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO), FUNDED BY THE US PRESIDENT'S MALARIA INITIATIVE (PMI). CALLED PAMO PLUS, THE PROJECT CONTINUES ITS PREDECESSOR'S MISSION OF ASSISTING THE GOVERNMENT OF ZAMBIA TO ELIMINATE MALARIA WITHIN ITS BORDERS. IN 2020, PAMO PROVIDED TECHNICAL SUPPORT AND MENTORSHIP TO MORE THAN 2,000 HEALTH CARE PROVIDERS AND TRAINED 1,098 COMMUNITY HEALTH WORKERS AND THEIR 272 SUPERVISORS IN COMMUNITY-LEVEL CASE MANAGEMENT AND SURVEILLANCE. PAMO/PAMO PLUS ALSO SUPPORTED THE DISTRIBUTION OF 122,602 INSECTICIDE-TREATED BEDNETS, ORGANIZED SOCIAL BEHAVIOR CHANGE ACTIVITIES (INCLUDING IN SCHOOLS), AND PROVIDED TECHNICAL AND MATERIAL SUPPORT FOR DATA QUALITY AUDITS IN HEALTH FACILITIES.PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS IN 2020 WITH OUR PARTNERS UNDER PMI VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA, WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB); WE ALSO COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND UK-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM. IN ADDITION, PATH LED A USAID INITIATIVE TO SUPPORT US GOVERNMENT INVESTMENTS IN MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION INTERVENTIONS. IN SENEGAL AND DRC, PATH BEGAN WORK TO INTEGRATE THE DATA VISUALIZATION DASHBOARDS OF THE NATIONAL EMERGENCY OPERATIONS CENTERS AND NATIONAL MALARIA CONTROL PROGRAMS AND DEVELOP IN-COUNTRY CAPACITY FOR DATA USE. THESE EFFORTS HELPED BOTH COUNTRIES RESPOND TO COVID-19 AND MITIGATE THE VIRUS' IMPACT ON MALARIA CONTROL AND ELIMINATION. PATH AND A PRIVATE-SECTOR TECHNOLOGY PARTNER, BLUESQUARE, SUPPORTED THE DRC MINISTRY OF HEALTH (MOH) TO STRENGTHEN COVID-19 CASE TRACKING AND CONTACT TRACING.AT THE ONSET OF COVID-19, THE PATH LABORATORY TEAM IN ZAMBIA PIVOTED FROM MALARIA TO WHOLE GENOME SEQUENCING OF SARS-COV-2 (THE VIRUS RESPONSIBLE FOR COVID-19) THROUGH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION AND IN COLLABORATION WITH THE UNIVERSITY OF ZAMBIA SCHOOL OF VETERINARY MEDICINE. THE LABORATORY'S WORK ENABLED IDENTIFICATION OF THE BETA (B.1.351) VARIANT OF CONCERN IN ZAMBIA, WHICH WAS ASSOCIATED WITH A MAJOR SECOND WAVE OF COVID-19 IN THE COUNTRY. THE LABORATORY'S WORK ALSO LED TO ESTABLISHMENT OF A NATIONAL SPECIMEN COLLECTION SYSTEM THROUGH THE ZAMBIA NATIONAL PUBLIC HEALTH INSTITUTE.THE VIVACCESS PROJECT, WHICH FOCUSES ON RADICAL CURE (ELIMINATION OF DORMANT LIVER-STAGE PARASITES) OF PLASMODIUM VIVAX MALARIA, CONTINUED TO SUPPORT INTRODUCTION OF G6PD TESTS AND OTHER RADICAL CURE PRODUCTS IN BRAZIL, CAMBODIA, COLOMBIA, ETHIOPIA, INDIA, LAOS, MYANMAR, PERU, THAILAND, AND VIETNAM. VIVACCESS ENGAGED WITH NORMATIVE POLICY BODIES SUCH AS THE WORLD HEALTH ORGANIZATION (WHO), PROMOTED MULTISTAKEHOLDER DISCUSSIONS THROUGH REGIONAL AND GLOBAL EVENTS, AND MUCH MORE. (ADDITIONAL WORK IN MALARIA IS COVERED IN THE CENTER FOR VACCINE INNOVATION AND ACCESS SECTION.)PATH'S EFFORTS TO ELIMINATE NEGLECTED TROPICAL DISEASES CONTINUED IN 2020 IN THE DRC, WHERE WE WORKED TO COMBAT HUMAN AFRICAN TRYPANOSOMIASIS (HAT, OR "SLEEPING SICKNESS") IN COLLABORATION WITH THE COUNTRY'S NATIONAL PROGRAM FOR THE CONTROL OF HAT (PNLTHA). WITH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION, PATH PROVIDED LOGISTICAL AND OPERATIONAL SUPPORT TO THE PNLTHA IN ACTIVE AND PASSIVE CASE DETECTION AND VECTOR CONTROL. WE ALSO SUPPORTED ADVOCACY, SENSITIZATION, AND PROMOTION ACTIVITIES TO STRENGTHEN HAT ELIMINATION EFFORTS AT THE NATIONAL, PROVINCIAL, AND COMMUNITY LEVELS. IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE AT THE NATIONAL, STATE, AND SUB-STATE LEVELS. IN THE STATE OF UTTAR PRADESH, WE HELPED ENSURE TRANSMISSION OF VISCERAL LEISHMANIASIS STAYED AT OR BELOW ELIMINATION LEVEL IN ENDEMIC DISTRICTS THROUGH HIGH-QUALITY SURVEILLANCE, ACTIVE CASE DETECTION, AND VECTOR CONTROL. PATH ALSO PROVIDED TECHNICAL ASSISTANCE FOR LYMPHATIC FILARIASIS (ELEPHANTIASIS) ELIMINATION THROUGH MASS DRUG ADMINISTRATION AND HELPED ESTABLISH A TECHNICAL SUPPORT UNIT FOR DENGUE-CHIKUNGUNYA CONTROL AND MALARIA ELIMINATION. HIV AND TUBERCULOSISPATH'S HIV AND TUBERCULOSIS (TB) PROGRAMMING REACHES GENERAL POPULATIONS AS WELL AS KEY POPULATIONS AFFECTED BY HIV/TB.IN 2020, AS THE COVID-19 RESPONSE HINDERED ACCESS TO HEALTH FACILITIES IN MANY COUNTRIES, PATH MOVED RAPIDLY TO MINIMIZE THE IMPACT ON HIV AND TB SERVICES. PATH USED AN APPROACH OF PROTECT-MITIGATE-SUPPORT: UNDER THE "PROTECT" PILLAR, WE EQUIPPED AND TRAINED FRONTLINE HEALTH CARE PROVIDERS TO TRIAGE AND DELIVER SERVICES TO PEOPLE WITH COVID-19 EXPOSURE OR SYMPTOMS. UNDER THE "MITIGATE" PILLAR, WE ADAPTED WHERE AND HOW HIV AND TB SERVICES WERE OFFERED, SHIFTING TOWARD VIRTUAL, COMMUNITY, AND PRIVATE-SECTOR DELIVERY MODALITIES AND MULTI-MONTH DRUG DISPENSING TO REDUCE THE NEED FOR CLINIC VISITS. UNDER THE "SUPPORT" PILLAR, WE USED EXISTING HIV AND TB PLATFORMS TO DISSEMINATE INFORMATION ON COVID-19, AND WE ADAPTED TB SCREENING PROTOCOLS TO INCLUDE SCREENING AND TRIAGE FOR COVID-19 (AND VICE VERSA). IN THE DRC, UNDER THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT, PATH INTRODUCED ASSISTED HIV SELF-TESTING (HIVST) VIA PHARMACISTS, ALTERNATIVE MEDICINE PROVIDERS, AND COMMUNITY HEALTH WORKERS. WE TESTED APPROXIMATELY 180,000 PEOPLE, ENROLLED AROUND 12,400 NEWLY IDENTIFIED PEOPLE LIVING WITH HIV (PLHIV) ON ANTIRETROVIRAL THERAPY (ART), AND SUPPORTED MORE THAN 43,800 INDIVIDUALS TO CONTINUE TREATMENT. IN WESTERN KENYA, UNDER THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF-FUNDED AFYA ZIWANI PROJECT, PATH EVOLVED OUR APPROACH, PARTICULARLY FOR HIV-NEGATIVE AGYW. THE PROJECT CREATED WHATSAPP-BASED VIRTUAL SAFE SPACES AND MOBILE, HOME-BASED SAFE SPACES TO ENSURE AGYW CONTINUED TO RECEIVE INFORMATION, COUNSELING, AND OTHER SERVICES DURING THE COVID-19 PANDEMIC; WE ALSO USED THESE SPACES TO DISSEMINATE INFORMATION ON COVID-19. THE PROJECT HOME-DELIVERED APPROXIMATELY 800 HIV PRE-EXPOSURE PROPHYLAXIS REFILLS AND MORE THAN 8,000 HIVST KITS FOR AGYW, WITH NO HIV-POSITIVE RESULTS. ACROSS ALL POPULATION GROUPS, AFYA ZIWANI TESTED MORE THAN 140,000 PEOPLE FOR HIV, LINKED ABOUT 3,500 NEWLY IDENTIFIED PLHIV TO ART, AND SUPPORTED A COHORT OF 25,600 PEOPLE ON TREATMENT. 92606261 34739083 ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE. IN RESPONSE TO THE COVID-19 PANDEMIC, PATH MOBILIZED QUICKLY TO DEPLOY OUR END-TO-END IMMUNIZATION EXPERTISE. WE PROVIDED POLICY AND FINANCIAL ADVICE TO GAVI ON DESIGN OF THE COVAX FACILITY WITH THE GOAL OF EQUITABLE COVID-19 VACCINE ACCESS AND DELIVERY WORLDWIDE. WE SECURED INITIAL FUNDING TO ADVANCE A LOW-COST COVID-19 VACCINE CANDIDATE (NDV-HXP-S) BASED ON TECHNOLOGIES DEVELOPED BY THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI AND THE UNIVERSITY OF TEXAS AT AUSTIN THAT IS TARGETED FOR EMERGING COUNTRY VACCINE MANUFACTURERS. ACROSS THE COVID-19 VACCINE DEVELOPMENT ECOSYSTEM, WE SUPPORTED VACCINE DEVELOPMENT AND CLINICAL SITE READINESS; PROVIDED CHEMISTRY, MANUFACTURING, AND CONTROL EXPERTISE TO MANUFACTURERS; AND LENT OUR CLINICAL, TECHNICAL, AND REGULATORY EXPERTISE TO DEVELOPERS AND COVID-19 CONSORTIA.IN 2020, PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. THE NOVEL ORAL POLIO VACCINE AGAINST TYPE 2 POLIOVIRUS (NOPV2) ACHIEVED A MAJOR MILESTONE WHEN IT BECAME THE FIRST VACCINE TO RECEIVE A WHO EMERGENCY USE LISTING (EUL). AS THE CONVENOR OF THE NOPV2 CONSORTIUM, PATH CONTRIBUTED KEY EVIDENCE AND SUPPORTED THE MANUFACTURER'S SUCCESSFUL EUL APPLICATION. THROUGHOUT 2020, PATH AND OUR COUNTRY PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. WRAPPING UP A REMARKABLE 17-YEAR GLOBAL PARTNERSHIP, PATH COMPLETED TWO STUDIES EXAMINING JE VACCINE DURATION OF PROTECTION AND CO-ADMINISTRATION AND FINALIZED A SUITE OF MATERIALS OUTLINING THE LESSONS AND STORY OF JE VACCINATION EFFORTS. ALSO IN 2020, WE CONTINUED A PIVOTAL, PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE ALSO CONTRIBUTED TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL "DEFEATING MENINGITIS BY 2030" INITIATIVE, WHICH CULMINATED IN WORLD HEALTH ASSEMBLY ADOPTION OF THE FIRST-EVER RESOLUTION ON MENINGITIS PREVENTION AND CONTROL AND ENDORSEMENT OF A GLOBAL ROAD MAP TO DEFEAT MENINGITIS.TO PREVENT MALARIA, PATH ACCELERATED THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. FOR EXAMPLE, WE WORKED WITH WHO AND OTHER PARTNERS, INCLUDING THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI, TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. WE ALSO CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. ADDITIONALLY, WORK CONTINUED ON EFFORTS TO IDENTIFY IMMUNE CORRELATES OF PROTECTION AND STUDY THE USE OF MONOCLONAL ANTIBODIES TO COMBAT MALARIA. IN 2020, PATH RECEIVED A FIVE-YEAR GRANT FROM USAID TO ADVANCE PRE-ERYTHROCYTIC, BLOOD-STAGE, AND COMBINATION MALARIA VACCINE CANDIDATE APPROACHES.THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE. A MAJOR FOCUS OF 2020 WAS A CAMPAIGN TO MAINTAIN CHILD HEALTH INVESTMENTS DURING THE COVID-19 PANDEMIC, INCLUDING STEADY ACCESS TO ESSENTIAL MEDICINES AND ROUTINE IMMUNIZATION. IN ONGOING EFFORTS TO SUPPORT LOCAL VACCINE PRODUCTION, PATH SUPPORTED VIETNAM-BASED MANUFACTURER POLYVAC TO COMPLETE CLINICAL TRIALS FOR THE LIQUID FORMULATION OF ROTAVIN VACCINE. OUR PHASE 3 STUDY FOUND THAT ROTAVIN IS AS SAFE AND IMMUNOGENIC AS THE CURRENTLY LICENSED FROZEN FORMULATION, ROTAVIN-M1. WE COMPLETED THE CLINICAL PHASE OF A PHASE 1 STUDY IN THE UNITED STATES OF A NOVEL, INJECTABLE SUBUNIT SHIGELLA VACCINE CANDIDATE AND INITIATED FOLLOW-ON EXPLORATORY IMMUNOLOGY ANALYSES USING SAMPLES FROM THE STUDY. AND WE CONTINUED TO HELP INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ROTAVIRUS VACCINES.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. WE SUPPORTED INVENTPRISE, A BIOTECHNOLOGY COMPANY, AS IT WORKS TO DEVELOP A MULTIVALENT, CONJUGATE VACCINE FOR LOW- AND MIDDLE-INCOME COUNTRIES. THE INTENDED RECIPIENTS ARE PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES. WITH OUR SUPPORT, THE GOVERNMENTS OF MALAWI AND NEPAL MADE THE DECISION TO INTRODUCE TCV AND SUCCESSFULLY APPLIED FOR ASSISTANCE FROM GAVI. PATH ALSO WORKED WITH THE GOVERNMENT OF KENYA ON ITS DECISION TO INTRODUCE TCV AND BEGIN PLANNING. TO ACCOUNT FOR CHALLENGES BROUGHT ON BY THE COVID-19 PANDEMIC, WE HELPED THE GOVERNMENTS OF LIBERIA, PAKISTAN, AND ZIMBABWE ADJUST THEIR TCV CAMPAIGNS.ALSO IN 2020, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO ANALYZE EVIDENCE ON SINGLE-DOSE HPV VACCINATION. FOR COUNTRIES WITH FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO INTRODUCTION, A SINGLE-DOSE REGIMEN COULD BE TRANSFORMATIVE. AMONG OTHER ASSISTANCE, OUR GLOBAL TEAM AND PARTNERS HELPED GAVI-ELIGIBLE COUNTRIES RESPOND TO THE COVID-19 PANDEMIC BY PIVOTING HPV VACCINATION PROGRAMS TO REACH OUT-OF-SCHOOL GIRLS.DRUG DEVELOPMENTTHROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE-FROM EARLY RESEARCH TO INTRODUCTION.IN 2020, WE COMPLETED A PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL OF IOWH032, A NOVEL ANTISECRETORY DRUG CANDIDATE FOR THE TREATMENT OF CHOLERA. WHILE IOWH032 WAS NOT EFFICACIOUS IN THIS STUDY, WE LEARNED IMPORTANT LESSONS FOR FUTURE DRUG TRIALS AND CONTINUE TO EXPLORE OTHER USES OF THIS COMPOUND, INCLUDING FOR TREATMENT OF COVID-19, CYSTIC FIBROSIS, AND POTENTIALLY OTHER INDICATIONS.IN ADDITION, WE CONTINUED OUR WORK ON DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. WE CONDUCTED KEY PRECLINICAL STUDIES AND SELECTED A COMPOUND FOR LARGE-ANIMAL EFFICACY TRIALS.THE DIARRHEA INNOVATIONS GROUP, AN INTERNATIONAL NETWORK OF CHILD HEALTH STAKEHOLDERS HOUSED WITHIN AND CO-CHAIRED BY PATH, CONTINUED TO ADVOCATE IN SUPPORT OF A LIFESAVING TREATMENT FOR DIARRHEA IN CHILDREN: THE USE OF CO-PACKAGED ORAL REHYDRATION SOLUTION AND ZINC, RECOGNIZED BY WHO AS AN ESSENTIAL MEDICINE. INCREASED ACCESS TO THIS TREATMENT COULD ACCELERATE PROGRESS TOWARD CHILD HEALTH GOALS.WITH OUR MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE MOVED TOWARD COMMERCIALIZATION OF A NEW TOOL FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION-AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE. 32223655 7574230 TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI) DIVISION IS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT MEDICAL DEVICES, HEALTH TECHNOLOGIES, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. TAMI ALSO MANAGES PATH'S WORK IN MARKET DYNAMICS AND DIGITAL AND DATA EXCELLENCE.(CONTINUED ON SCHEDULE O)MEDICAL DEVICES AND HEALTH TECHNOLOGIESTHE MEDICAL DEVICES AND HEALTH TECHNOLOGIES (MDHT) PROGRAM WITHIN TAMI IS PATH'S PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.MILESTONES IN 2020 INCLUDED BEGINNING THE WORLD'S FIRST FREEZE-PREVENTIVE COLD BOX EVALUATION IN NEPAL; COMPLETING A THREE-YEAR INTRODUCTION AND SCALE-UP OF 7.1 PERCENT CHLORHEXIDINE FOR UMBILICAL CORD CARE IN FRANCOPHONE WEST AFRICA; RECEIVING REGULATORY APPROVAL IN GHANA AND KENYA FOR THE ELLAVI UTERINE BALLOON TAMPONADE-A PATH-DEVELOPED, LIFESAVING MEDICAL DEVICE FOR POSTPARTUM HEMORRHAGE; AND SERVING AS A KEY PARTNER ON THE GAVI-LED VACCINE INNOVATION PRIORITIZATION STRATEGY.MDHT ALSO ADDRESSED THE COVID-19 PANDEMIC: ONE EFFORT AIMED TO ACCELERATE EQUITABLE GLOBAL ACCESS TO COVID-19 VACCINES THROUGH A COLLABORATION WITH UNICEF AND THE COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS. WORKING CLOSELY WITH PATH'S CENTER FOR VACCINE INNOVATION AND ACCESS, MDHT ASSESSED THE GLOBAL SUPPLY CHAIN FOR VACCINE COMPONENTS, VACCINE MANUFACTURING CAPACITY, SYRINGE AVAILABILITY, AND COLD CHAIN AND ULTRA-COLD CHAIN CAPACITY. WE ALSO ASSESSED COVID-19 VACCINE COLLATERAL MATERIALS AND INFORMATION-FOR EXAMPLE, NEW PACKAGING AND DELIVERY TECHNOLOGIES, WHO LABELING GUIDELINES, AND E-LEARNING MODULES.MDHT'S LIVING LABS INITIATIVE USED HUMAN-CENTERED DESIGN METHODS IN KENYA AND ZAMBIA TO IDENTIFY CHALLENGES AND PROPOSE SOLUTIONS TO THE MANY OBSTACLES IMMUNIZATION WORKERS FACE. IN KENYA, THE LIVING LABS TEAM ENGAGED HEALTH CARE WORKERS TO IDENTIFY CHALLENGES IN MANAGING POSTPARTUM HEMORRHAGE AND PRIORITIZE SOLUTIONS FOR GOVERNMENT RESPONSE. IN 2020, MDHT STAFF PRODUCED NINE PEER-REVIEWED JOURNAL ARTICLES AND RESEARCH REPORTS ON TOPICS RANGING FROM FREEZE-DRIED TABLETS FOR ORAL VACCINE DELIVERY TO CHLORHEXIDINE FOR FACILITY-BASED UMBILICAL CORD CARE.LAST, A CONSULTANT HIRED BY THE PATH SOUTH AFRICA IMPACT LAB WORKED CLOSELY WITH THE GLOBAL HEALTH INNOVATION ACCELERATOR/SOUTH AFRICAN MEDICAL RESEARCH COUNCIL ON A MEDICAL DEVICE LANDSCAPING ACTIVITY DESIGNED TO ACCELERATE PRODUCTION AND INTRODUCTION OF NOVEL HEALTH TECHNOLOGIES.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM ADVANCES EQUITABLE AND SUSTAINABLE ACCESS TO AFFORDABLE, QUALITY-ASSURED DIAGNOSTICS FOR BETTER DIAGNOSIS AND TREATMENT IN LOW-RESOURCE SETTINGS.IN 2020, OUR PIONEERING WORK INCLUDED DEVELOPING, VALIDATING, EVALUATING, AND COMMERCIALIZING TESTS, REFERENCE ASSAYS, AND TOOLS; CONDUCTING LABORATORY PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; FACILITATING A G6PD OPERATIONAL RESEARCH COMMUNITY OF PRACTICE; AND PUBLISHING 15 PEER-REVIEWED JOURNAL ARTICLES.THE DIAGNOSTICS TEAM RAPIDLY RESPONDED TO THE GLOBAL COVID-19 PANDEMIC WITH LABORATORY-BASED ACTIVITIES TO SUPPORT DIAGNOSTIC DEVELOPERS. THIS INCLUDED CREATING A BIOREPOSITORY OF QUALIFIED COVID-19 CLINICAL SAMPLES TO ACCELERATE THE DEVELOPMENT AND VALIDATION OF NEW COVID-19 DIAGNOSTIC TESTS (PROVIDED FREE OF CHARGE TO DEVELOPERS INTENDING TO SUPPLY GLOBAL MARKETS); CREATING FIVE DIGITAL, INTERACTIVE COVID-19 DIAGNOSTICS DASHBOARDS THAT AGGREGATE AND VISUALIZE PUBLICLY AVAILABLE INFORMATION ON THE DEVELOPMENT, SUPPLY, REGULATORY APPROVAL, AND PERFORMANCE OF COVID-19 DIAGNOSTIC TESTS (TO SUPPORT PRODUCT SELECTION AND PROCUREMENT DECISIONS WORLDWIDE); CONDUCTING IN-HOUSE EVALUATIONS OF NEW COMMERCIAL RAPID DIAGNOSTIC TESTS TO VERIFY PERFORMANCE CLAIMS AND FIT-FOR-PURPOSE IN INTERNATIONAL SETTINGS; ENSURING THE QUALITY OF COVID-19 RAPID DIAGNOSTIC TESTS WITH A BENCHMARKING PANEL THAT ENABLES UNBIASED, COMPARATIVE EVALUATIONS BETWEEN COVID-19 TESTS; SUPPORTING THE NATIONAL RESPONSE IN INDONESIA, MALAWI, NEPAL, AND PAKISTAN WITH ENVIRONMENTAL SURVEILLANCE DATA COLLECTION PROJECTS TO DETECT AND QUANTIFY THE PRESENCE OF SARS-COV-2 IN IMPACTED WASTEWATER; AND ENSURING THAT COVID-19 POINT-OF-CARE TESTS ARE SUITABLE FOR CLINICAL AND OPERATIONAL STUDIES IN BRAZIL.IN PARTNERSHIP WITH THE UNIVERSITY OF QUEENSLAND, THE DIAGNOSTICS TEAM SUPPORTED THE COMMERCIALIZATION OF CUSTOM MALARIA PROTEINS TO FACILITATE PERFORMANCE BENCHMARKING OF RAPID, ACCURATE, AND SPECIES-SPECIFIC MALARIA DIAGNOSTIC TESTS.THE TEAM ALSO SUBMITTED REGULATORY DOSSIERS FOR THE SD BIOSENSOR STANDARD G6PD TEST, WHICH GUIDES THE TREATMENT OF PLASMODIUM VIVAX MALARIA, TO THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION, THE US FOOD AND DRUG ADMINISTRATION, AND WHO FOR PREQUALIFICATION. IN 2020, NEARLY 75,000 OF THESE TESTS WERE DISTRIBUTED TO 30 COUNTRIES.INDIA IMPACT LABINDIA HAS A RICH INNOVATION ECOSYSTEM WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON DEVELOPING PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE. PATH'S INDIA IMPACT LAB, A PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI, IS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE. THE IMPACT LAB PARTNERS WITH TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES. IN 2020, THE IMPACT LAB LED PATH'S PARTNERSHIP WITH THE CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS, A PUBLIC-PRIVATE INITIATIVE THAT LAUNCHED THE COVID-19 INNOVATIONS DEPLOYMENT ACCELERATOR (C-CIDA) IN MARCH 2020. C-CIDA HELPS FAST-TRACK INNOVATIONS IN SCREENING, DIAGNOSIS, TREATMENT, MONITORING, CARE, AND MANAGEMENT OF COVID-19. THE IMPACT LAB CONTINUED TO SUPPORT THE MARKET ACCESS PROGRAM OF THE INDIA NATIONAL HEALTH AUTHORITY AND PARTNERED WITH XYNTEO INDIA ON PROJECT TEJ, AN INITIATIVE OF THE TELANGANA STATE GOVERNMENT AND MEDTECH CONNECT TO ACCELERATE INDIAN MEDICAL TECHNOLOGY INNOVATIONS. IN ADDITION, THE IMPACT LAB MANAGED A PIPELINE OF INNOVATIONS BEING EXPLORED FOR INTEGRATION WITH PRIMARY HEALTH CARE, IMMUNIZATION, NUTRITION, TB, COVID-19, FAMILY PLANNING, AND REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH PROGRAMS.THE IMPACT LAB ALSO CONTINUED ITS CROSSCUTTING SUPPORT OF VARIOUS PROGRAMS AT PATH; FOR EXAMPLE, EVALUATING LOW-FIELD MAGNETIC RESONANCE IMAGING, IMPROVING ACCESS TO COVID-19 TESTING IN INDIA THROUGH SYSTEM STRENGTHENING, EVALUATING A BLOW-FILL-SEAL ORAL VACCINE RECONSTITUTION DELIVERY SYSTEM, AND MARKET RESEARCH FOR NEWBORN SCREENING AND G6PD TESTING IN THE PRIVATE HEALTH SECTOR. MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM WORKS TO IMPROVE HEALTH EQUITY AND HEALTH OUTCOMES BY EVALUATING MARKETS, ASSESSING ROOT CAUSES OF LIMITED ACCESS TO HEALTH CARE PRODUCTS AND SERVICES, AND DESIGNING AND IMPLEMENTING MARKET-BASED INTERVENTIONS TO INCREASE ACCESS. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT/INTRODUCTION AND HEALTH SYSTEMS STRENGTHENING AND IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, AND PATH'S COUNTRY PROGRAMS.IN 2020, OUR WORK WAS FOCUSED PRIMARILY ON IMPROVING ACCESS TO MEDICAL OXYGEN AND RELATED RESPIRATORY CARE PRODUCTS FOR COVID-19 TREATMENT AS WELL AS MALARIA DRUGS AND DIAGNOSTICS.CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2020, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE (CODE) APPLIED ITS EXPERTISE TO ACCELERATE COUNTRY-LED DIGITAL HEALTH, DEEPEN THE USE OF DATA, AND SUPPORT THE GLOBAL COVID-19 RESPONSE. KEY ACCOMPLISHMENTS INCLUDED CO-AUTHORING WHO'S DIGITAL IMPLEMENTATION INVESTMENT GUIDE, WHICH OFFERS A SYSTEMIC PROCESS FOR COUNTRIES TO DEVELOP COSTED IMPLEMENTATION PLANS FOR DIGITAL HEALTH. DIGITAL SQUARE, A PATH-LED INITIATIVE, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES. DIGITAL SQUARE LED THE HEALTH DATA SCIENCE EXCHANGE, AN EXPLORATORY EFFORT TO UNDERSTAND HOW THE GREATER COORDINATION OF DATA SCIENCE TOOLS AND APPROACHES COULD IMPROVE HEALTH IMPACT. DIGITAL SQUARE ALSO BEGAN WORK ON MAP & MATCH, A LANDSCAPING ACTIVITY TO IDENTIFY EXISTING NATIONAL-LEVEL SOFTWARE TOOLS AND TECHNOLOGIES THAT CAN BE ADAPTED FOR COVID-19 RESPONSE. 23015170 5154512 ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. IN 2020, PATH LED EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES, EUROPE, AND MULTILATERAL AGENCIES TO MAINTAIN AND STRENGTHEN WORK IN RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY US GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS, ENSURING US RE-INVESTMENT IN THE NEXT PHASE OF GAVI, AND HELPING DECISION-MAKERS CRAFT EMERGENCY FUNDING FOR THE GLOBAL RESPONSE TO COVID-19. WORKING WITH PARTNERS IN AFRICA, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN AND PROTECT ESSENTIAL HEALTH SERVICES AS THE COVID-19 PANDEMIC TOOK AN UNPRECEDENTED TOLL ON HEALTH SYSTEMS; FOR EXAMPLE, IN KENYA, OUR ADVOCACY RESULTED IN ESTABLISHMENT OF THE GLOBAL FINANCING FACILITY'S MULTI-STAKEHOLDER COUNTRY PLATFORM, WHICH GIVES CIVIL SOCIETY A VOICE IN GOVERNMENT FUNDING OF MATERNAL AND CHILD HEALTH PROGRAMS. IN SOUTH AFRICA, WE SUPPORTED THE COUNTRY'S HEALTH REGULATORY AGENCY AS IT STREAMLINED AND DISSEMINATED INFORMATION ABOUT THE APPROVAL PIPELINE FOR COVID-19 TOOLS AND TREATMENTS. IN UGANDA, WE SUCCESSFULLY ADVOCATED FOR INCREASED FUNDING FOR PRIMARY HEALTH CARE AND SUPPORTED THE NATIONAL IMMUNIZATION PROGRAM IN DEVELOPING A PLAN TO ROLL OUT COVID-19 VACCINATION AND CATCH UP ON MISSED IMMUNIZATIONS DURING THE PANDEMIC. AND IN THE DRC, WE SUCCESSFULLY ADVOCATED FOR FULL DISBURSEMENT OF THE GOVERNMENT'S CO-FINANCING COMMITMENTS TO GAVI AS WELL AS ADDITIONAL FUNDS FOR IMMUNIZATION IN THREE PROVINCES.SPECIAL INITIATIVESPATH IS ENGAGED IN A VARIETY OF SPECIAL INITIATIVES THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. BY THE END OF 2020, WE HAD ACTIVE HEALTH IMPACT TEAMS IN SEVEN HEALTH AREAS. EACH HEALTH IMPACT TEAM HAS BEEN ONGOING FOR AT LEAST THREE YEARS, WORKING TO BUILD STRUCTURED COLLABORATION ACROSS PROGRAMS AND GEOGRAPHIES TO INCREASE PATH'S IMPACT. 23015170 5154512 262890896 1 1 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 X 221 0 1 714 1 0 1 BE CH ET GH IN KE MZ PE SG SZ TZ UG UK VM ZA CG MI BM SF UP 0 0 0 0 0 0 0 0 0 0 X 15 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA CT FL IL KS KY MA MD MI MN MS NC NH NJ NM NY OK OR PA RI SC TN UT VA WI WV X X KELLY PRIESTLEY CONTROLLER 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 DAVID KING CHAIR 2.00 0.00 X X 0 0 0 BETH GALETTI VICE CHAIR 2.00 0.00 X X 0 0 0 YEHONG ZHANG SECRETARY 2.00 0.00 X X 0 0 0 BRUCE MCNAMER TREASURER 2.00 0.00 X X 0 0 0 FELIX OLALE DIRECTOR 2.00 0.00 X 0 0 0 JO ADDY DIRECTOR 2.00 0.00 X 0 0 0 IREENA VITTAL DIRECTOR 2.00 0.00 X 0 0 0 DEANNA OPPENHEIMER DIRECTOR (BEGAN 6/2020) 2.00 0.00 X 0 0 0 JOHN-ARNE ROTTINGEN DIRECTOR 2.00 0.00 X 0 0 0 JOEL HOLSINGER DIRECTOR 2.00 0.00 X 0 0 0 HELENA WAYTH DIRECTOR 2.00 0.00 X 0 0 0 SANFORD MELZER DIRECTOR 2.00 0.00 X 0 0 0 ABAYOMI SULE DIRECTOR 2.00 0.00 X 0 0 0 LISA ANDERSON DIRECTOR 2.00 0.00 X 0 0 0 RACHEL SIBANDE DIRECTOR 2.00 0.00 X 0 0 0 STEPHEN B DAVIS PRESIDENT AND CEO (RESIGNED 1/2020) 39.00 1.00 X 249057 0 13602 NIKOLAJ JESTED GILBERT PRESIDENT AND CEO (FROM 1/2020) 39.00 1.00 X 256555 315385 44054 JERRY KUO CHIEF OF STRATEGIC FINANCE 39.00 1.00 X 252897 0 58226 BRIAN N NEVILLE CHIEF OF ACCOUNTING 39.00 1.00 X 260514 0 36826 PHILIPPE GUINOT CHIEF OF BUSINESS, FIN. & OPS. 39.00 1.00 X 0 258031 22877 DAVID C KASLOW VP - ESSENTIAL MEDICNES 39.00 1.00 X 427937 0 69391 JEFFREY D BERNSON VP - TECH, ANALYTICS, MRKT INNOV. 40.00 0.00 X 322741 0 57193 DAVID W FLEMING VP - PUBLIC HEALTH 40.00 0.00 X 364555 0 44832 ELAINE L GIBBONS VP - GLOBAL ENGAGEMENT 39.00 1.00 X 291278 0 76724 MOLLI M BARNES CHIEF PEOPLE OFFICER 40.00 0.00 X 278509 0 52067 ERICA JANE SESSLE CHIEF OF STAFF 40.00 0.00 X 238815 0 54599 SABRINA L POWERS GENERAL COUNSEL 40.00 0.00 X 232450 0 37202 TRAD M HATTON COUNTRY DIRECTOR 40.00 0.00 X 376676 0 54537 JAMES B MCKENNA DEPUTY DIRECTOR 40.00 0.00 X 321745 0 84937 ASHLEY J BIRKETT GLOBAL HEAD, MALARIA VACCINES 40.00 0.00 X 346772 0 56185 BRUCE LAMONT INNIS GLOBAL HEAD, RESPIRATORY INFECTIONS 40.00 0.00 X 357737 0 32603 JOHN O KONZ GLOBAL HEAD, FINANCIAL MANAGEMENT 40.00 0.00 X 346902 0 67132 4925140 573416 862987 373 0 1 0 RANDSTAD INDIA PVT LTD SUIT NO 001 002 COPIA NEW DELHI IN 110025 STAFFING SERVICES 996065 SAFEGUARD WORLD INT'L MOSS LANE EDWIN FODEN BUS CENTRE SANDBACH UK CW113AE GENERAL CONTRACTOR 890294 WMBE PAYROLLING DBA TARGETCW 9475 CHESAPEAKE DR SAN DIEGO CA 92123 GENERAL CONTRACTOR 736559 JAMES G DAVIS CONTRUCTION CORPORATION 12530 PARKLAND DRIVE ROCKVILLE MD 20852 GENERAL CONTRACTOR 622327 INSTRUMENT LLC 3529 NORTH WILLIAMS AVENUE PORTLAND OR 97227 CONSULTING 488228 45 4386562 98650801 184417020 761052 287454383 12207084 12207084 57083069 21954 56797395 12461 285674 9493 295167 295167 REIMBURSEMENTS 900099 705455 705455 OTHER 900099 324657 324657 1030112 300986746 0 0 13532363 19808249 19808249 48186578 48186578 3696147 443030 3230480 22637 95455775 89233434 4839226 1383115 9902096 6999543 2788845 113708 16637172 13244535 3259730 132907 6405206 4527542 1804106 73558 805000 428419 376581 478838 186280 292558 1845 1845 177923 177923 15387022 12189851 3136788 60383 286728 220391 3897 62440 7780893 6665971 1027428 87494 1392563 390928 981124 20511 337136 337136 12679852 272765 12407087 7889458 7460553 423813 5092 5292304 5113342 174332 4630 1904 154 1750 3101076 12403 3088673 849014 210678 638336 SUBCONTRACTORS 26935850 26932945 2905 EQUIP RENT & MAINT 6595821 5287573 1303962 4286 DIRECT AID TO BENEFICIA 1393030 1393030 FACILITIES ALLOC 0 13189972 -13402840 212868 1582003 153749 1201997 226257 293059483 262890896 27758701 2409886 8845877 7194550 17517988 9719000 44215907 39742632 16731594 258036 7170218 7008112 38112788 29699485 9991630 8413303 138590941 211220570 243064155 283556203 204045574 234982056 204045574 234982056 X 20518990 21554594 18499591 27019553 39018581 48574147 243064155 283556203 7927263 1628303 0 X 0 1 X 1 1 1 X 298315988 347844394 305316107 286808545 287454383 1525739417 298315988 347844394 305316107 286808545 287454383 1525739417 686241805 839497612 1797794 2050888 2963587 6310221 12207084 25329574 4668393 5225302 980560 836870 1030112 12741237 1563810228 74952 0.53680 0.56000 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 405 134788 135193 292924290 293059483 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 294096 224944 163912 135193 818145 250000 250000 250000 250000 1000000 1500000 127336 7856 405 135597 10287113 2745 1095576 454711 10930723 9095917 2100 1691617 502521 10287113 10056545 1240 -494491 467377 9095917 9339249 3410 1159282 445396 10056545 8897224 4256 907978 470209 9339249 0.36000 0.31000 0.33000 0 0 22350295 15697322 6652973 10509124 8976229 1532895 5253369 5025934 227435 8413303 PART V, LINE 4: PATH UTILIZES THE INVESTED INTREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY. 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 3972740 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 223997 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 71241 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 282879 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES OTHER 18974 CENTRAL AMERICA AND THE CARIBBEAN 0 0 BID & PROPOSAL BID & PROPOSAL 17083 CENTRAL AMERICA AND THE CARIBBEAN 0 0 FUNDRAISING FUNDRAISING 88125 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTMAKING 101723 EAST ASIA AND THE PACIFIC 5 110 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 1168919 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 6333906 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 298774 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 253294 EAST ASIA AND THE PACIFIC 0 0 BID & PROPOSAL BID & PROPOSAL 62526 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES OTHER 40996 EAST ASIA AND THE PACIFIC 0 0 FUNDRAISING FUNDRAISING 2700 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 10343468 EUROPE 1 4 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 1574825 EUROPE 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 3336671 EUROPE 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 7675989 EUROPE 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 1469697 EUROPE 0 0 PROGRAM SERVICES OTHER 48919 EUROPE 0 0 BID & PROPOSAL BID & PROPOSAL 4900 EUROPE 0 0 GRANTMAKING 23791380 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 3238 NORTH AMERICA 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 74544 NORTH AMERICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 188511 NORTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 1164008 NORTH AMERICA 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 8008 NORTH AMERICA 0 0 PROGRAM SERVICES OTHER 15896 NORTH AMERICA 0 0 FUNDRAISING FUNDRAISING 4595 NORTH AMERICA 0 0 GRANTMAKING 383489 RUSSIA AND NEIGHBORING STATES 1 25 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 457221 RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 3283227 RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 1590 RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 3950 RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES OTHER 12 RUSSIA AND NEIGHBORING STATES 0 0 BID & PROPOSAL BID & PROPOSAL 1150 RUSSIA AND NEIGHBORING STATES 0 0 GRANTMAKING 1556551 SOUTH AMERICA 1 3 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 46002 SOUTH AMERICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 274890 SOUTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 7574 SOUTH AMERICA 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 60715 SOUTH AMERICA 0 0 PROGRAM SERVICES OTHER 1340 SOUTH AMERICA 0 0 BID & PROPOSAL BID & PROPOSAL 339 SOUTH AMERICA 0 0 GRANTMAKING 219648 SOUTH ASIA 6 133 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 2234260 SOUTH ASIA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 4834839 SOUTH ASIA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 1496048 SOUTH ASIA 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 435904 SOUTH ASIA 0 0 PROGRAM SERVICES OTHER 4000 SOUTH ASIA 0 0 BID & PROPOSAL BID & PROPOSAL 51747 SOUTH ASIA 0 0 GRANTMAKING 2491733 SUB-SAHARAN AFRICA 43 621 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 7301830 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 40342367 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 2110189 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 2250189 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OTHER 2228030 SUB-SAHARAN AFRICA 0 0 BID & PROPOSAL BID & PROPOSAL 206210 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 9298586 0 0 57 896 57 896 4776762 139449394 144226156 CENTRAL AMERICA AND THE CARIBBEAN GLOBAL HEALTH PROGRAMS 26270 CHECK/WIRE CENTRAL AMERICA AND THE CARIBBEAN GLOBAL HEALTH PROGRAMS 45720 CHECK/WIRE CENTRAL AMERICA AND THE CARIBBEAN GLOBAL HEALTH PROGRAMS 29733 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 40314 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 27468 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 37301 CHECK/WIRE EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 1101162 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 41367 CHECK/WIRE EAST ASIA AND THE PACIFIC TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 88615 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 103203 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 21619 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 236201 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 36707 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 150857 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 7196 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 17892 CHECK/WIRE EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 248606 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 40822 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 40286 CHECK/WIRE EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 14241 CHECK/WIRE EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 167362 CHECK/WIRE EAST ASIA AND THE PACIFIC TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 89721 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 122878 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 74096 CHECK/WIRE EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 51839 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 81635 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 122963 CHECK/WIRE EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 6022820 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 17200 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 133107 CHECK/WIRE EAST ASIA AND THE PACIFIC TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 90043 CHECK/WIRE EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 572600 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 175178 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 247758 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 12162 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 29370 CHECK/WIRE EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 20000 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 25962 CHECK/WIRE EAST ASIA AND THE PACIFIC GLOBAL HEALTH PROGRAMS 28454 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 732113 CHECK/WIRE EUROPE TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 179882 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 446581 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 286668 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 9377 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 1921597 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 36965 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 29264 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 891713 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 6572907 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 14025 CHECK/WIRE EUROPE TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 257454 CHECK/WIRE EUROPE TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 21720 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 20018 CHECK/WIRE EUROPE TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 235172 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 834665 CHECK/WIRE EUROPE TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 16465 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 108000 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 5475 CHECK/WIRE EUROPE TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 923552 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 1038048 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 85046 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 52330 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 15820 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 200378 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 375000 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 3748324 CHECK/WIRE EUROPE TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 23132 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 93845 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 80877 CHECK/WIRE EUROPE ESSENTIAL MEDICINE, GLOBAL HEALTH PROGRAMS, TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS, AND OTHER 4534968 CHECK/WIRE NORTH AMERICA ESSENTIAL MEDICINE 123207 CHECK/WIRE NORTH AMERICA GLOBAL HEALTH PROGRAMS 25000 CHECK/WIRE NORTH AMERICA ESSENTIAL MEDICINE 88141 CHECK/WIRE NORTH AMERICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 147141 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 24863 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 44978 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 13118 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 7300 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 67764 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 18856 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 61591 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 14589 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 75073 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 17646 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 430980 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 18758 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 22231 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 65868 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 15353 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 30681 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 32256 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 33427 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 114951 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 149600 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 58055 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 72813 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 9762 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 104693 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 23730 CHECK/WIRE RUSSIA AND NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 24210 CHECK/WIRE SOUTH AMERICA GLOBAL HEALTH PROGRAMS 108625 CHECK/WIRE SOUTH AMERICA GLOBAL HEALTH PROGRAMS 10816 CHECK/WIRE SOUTH AMERICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 16445 CHECK/WIRE SOUTH AMERICA GLOBAL HEALTH PROGRAMS 83762 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 175937 CHECK/WIRE SOUTH ASIA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 7801 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 285788 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 55019 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 87424 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 38652 CHECK/WIRE SOUTH ASIA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 24470 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 296153 CHECK/WIRE SOUTH ASIA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 137360 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 165311 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 79111 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 989230 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 84312 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 65165 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 13911 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 124740 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 104229 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 5046 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 145235 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 46437 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 26070 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 1616490 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 21305 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 6582 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 21615 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 1009409 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 820924 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 139523 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 437058 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 33819 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 37762 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 98022 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 26585 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 13210 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 25791 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 226644 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 12000 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 314600 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 54880 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 12911 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 6720 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 14480 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 125404 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 208292 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 39725 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 217405 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 184370 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 6883 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 134626 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS AND OTHER 47900 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 57658 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 69703 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 439709 CHECK/WIRE SUB-SAHARAN AFRICA OTHER 8659 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 18450 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 50069 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 6286 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 6271 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 5350 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 450000 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 8343 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 83928 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 45130 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 8795 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 6134 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 5787 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 67892 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 20000 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS 211644 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 7344 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 807930 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 426057 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 58129 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 7558 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 8775 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 19052 CHECK/WIRE 139 41 1 0 0 0 0 0 PART I, LINE 2: PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. PART III ACCOUNTING METHOD: 1 ADARA DEVELOPMENT (USA) 300 ADMIRAL WY SUITE 106 EDMONDS WA 98020 980634789 501(C)(3) 14499 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS BAGAMIAN SCIENTIFIC CONSULTING 222 NW 3RD AVE GAINESVILLE FL 32601 821347380 OTHER 24350 ESSENTIAL MEDICINE BEHAVIORAL IDEAS LAB INC (DBA IDEAS42) 80 BROAD STREET 30TH FLOOR NEW YORK NY 10004 271678009 501(C)(3) 85721 GLOBAL HEALTH PROGRAMS BIOIVT LLC 123 FROST ST STE 115 WESTBURY NY 11590 271867431 OTHER 38950 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS CENTERS FOR DISEASE CONTROL AND PREVENTION 1600 CLIFTON ROAD ATLANTA GA 30333 586051157 GOV 71016 ESSENTIAL MEDICINE CHILDREN'S HOSPITAL BOSTON RESEARCH FINANCE PO BOX 414413 BOSTON MA 022414413 042774441 501(C)(3) 599612 ESSENTIAL MEDICINE CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVE ML 6014 CINCINNATI OH 452293039 310833936 501(C)(3) 407166 ESSENTIAL MEDICINE CLINTON HEALTH ACCESS INITIATIVE 383 DORCHESTER AVE SUITE 400 BOSTON MA 02127 271414646 501(C)(3) 2624024 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS COOPERSMITH 4206 RIVER RD NW WASHINGTON DC 20016 472387850 OTHER 116315 GLOBAL HEALTH PROGRAMS DIMAGI INC 585 MASSACHUSETTS AVE SUITE 4 CAMBRIDGE MA 02139 830343298 501(C)(3) 40477 GLOBAL HEALTH PROGRAMS FINA BIOSOLUTIONS LLC 9430 KEY WEST AVE SUITE 200 ROCKVILLE MD 20850 205448275 OTHER 217000 ESSENTIAL MEDICINE FOOD AND DRUG ADMINISTRATION 5600 FISHERS LANEHFA-140 ROOM 11-40 11-40 ROCKVILLE MD 20857 530196965 GOV 103750 ESSENTIAL MEDICINE FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N PO BOX 19024 SEATTLE WA 981091024 237156071 501(C)(3) 26177 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS G&L SCIENTIFIC INC 25 INDEPENDENCE BLVD SUITE 404 WARREN NJ 07059 811114075 OTHER 8185 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS GLOBAL CONNECT DEVELOPMENT GROUP LLC 480 BEACH ST BOSTON MA 02131 823433604 OTHER 71525 GLOBAL HEALTH PROGRAMS GLOBAL HEALTH CORPS 318 WEST 39TH STREET ROOM 9L NEW YORK NY 10018 800512336 501(C)(3) 6045 GLOBAL HEALTH PROGRAMS GLOBAL HEALTH STRATEGIES LLC 27 WEST 24TH STREET SUITE 900 NEW YORK NY 10010 272494697 501(C)(3) 280713 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS GUARALDI SYSTEMS LLC 97 ALGER BROOK RD SOUTH STAFFORD VT 05070 851148274 OTHER 117040 GLOBAL HEALTH PROGRAMS HARVARD SCHOOL OF PUBLIC HEALTH 677 HUNTINGTON AVENUE BOSTON MA 02215 042103580 501(C)(3) 691653 ESSENTIAL MEDICINE HARVARD UNIVERSITY 1033 MASSACHUSETTS AVE 2ND FLOOR CAMBRIDGE MA 02115 042103580 501(C)(3) 165466 ESSENTIAL MEDICINE AND GLOBAL HEALTH PROGRAMS HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC 6720-A ROCKLEDGE DRIVE STE 100 BETHESDA MD 20817 521317896 501(C)(3) 69910 ESSENTIAL MEDICINE HISP US LLC 31 ANCONA AVE OCEAN PARK ME 04063 850894858 OTHER 121924 GLOBAL HEALTH PROGRAMS HJF MEDICAL RESEARCH INTERNATIONAL INC 6720A ROCKLEDGE DRIVE SUITE 100 BETHESDA MD 20817 522322791 501(C)(3) 815715 ESSENTIAL MEDICINE ICF MACRO INC 9300 LEE HIGHWAY FAIRFAX VA 22031 223661438 OTHER 1432031 GLOBAL HEALTH PROGRAMS INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE ( IFPRI ) 1201 EYE STREET NW WASHINGTON DC 20005 521041632 501(C)(3) 118841 GLOBAL HEALTH PROGRAMS INTRAHEALTH INTERNATIONAL INC 6340 QUADRANGLE DRIVE SUITE 200 CHAPEL HILL NC 27517 550825466 501(C)(3) 490617 GLOBAL HEALTH PROGRAMS IPAS 300 MARKET ST 200 CHAPEL HILL NC 27516 561071085 501(C)(3) 20000 GLOBAL HEALTH PROGRAMS JHPIEGO 1615 THAMES STREET SUITE 200 BALTIMORE MD 212313447 237424444 501(C)(3) 59904 GLOBAL HEALTH PROGRAMS JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHL OF PUB HLTH 615 N WOLFE STREET BALTIMORE MD 21205 520595110 501(C)(3) 47858 GLOBAL HEALTH PROGRAMS JSI RESEARCH AND TRAINING INSTITUTE INC 1616 NORTH FORT MYER DR 16TH FLOOR ARLINGTON VA 222093100 042679824 501(C)(3) 1101159 GLOBAL HEALTH PROGRAMS LINKSBRIDGE SPC 101 TAYLOR AVE N 105 SEATTLE WA 98109 263067893 OTHER 57926 ESSENTIAL MEDICINE MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION 3339 WARD ST PITTSBURGH PA 15213 251462312 501(C)(3) 13300 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS MANAGEMENT SCIENCES FOR HEALTH INC 200 RIVERS EDGE DRIVE SUITE 320 MEDFORD MA 02155 042482188 501(C)(3) 60827 GLOBAL HEALTH PROGRAMS MASS DESIGN GROUP LTD 334 BOYLSTON ST STE 400 BOSTON MA 02116 611659704 501(C)(3) 50000 GLOBAL HEALTH PROGRAMS MASSACHUSETTS GENERAL HOSPITAL DEPT OF EMERGENCY MEDICINE ZERO EMERSON PL 104 BOSTON MA 02114 041564655 501(C)(3) 236406 ESSENTIAL MEDICINE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 20443 ESSENTIAL MEDICINE MEDIC MOBILE INC 3254 19TH STREET FLOOR 2 SAN FRANCISCO CA 94110 275104203 501(C)(3) 31647 GLOBAL HEALTH PROGRAMS MICHIGAN STATE UNIVERSITY 3900 COLLINS RD SUITE 1044 LANSING MI 48910 386005984 501(C)(3) 132399 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS MICRON BIOMEDICAL INC 311 FERST DR NW SUITE L1309 ATLANTA GA 30332 471692844 OTHER 113633 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS NATIONAL FOUNDATION FOR THE CDC 55 PARK PLACE SUITE 400 ATLANTA GA 30303 582106707 501(C)(3) 185563 ESSENTIAL MEDICINE NAT'L INST OF ALLERGY & INFECTIOUS DISEASES 6610 ROCKLEDGE DR ROOM 2800 BETHESDA MD 208926606 520858115 GOV 480134 ESSENTIAL MEDICINE NICHOLAS INSTITUTE FOR ENVIRONMENTAL POLICY SOLUTIONS AT DUKE UNIVERSITY 2117 CAMPUS DRIVE PO BOX 90335 DURHAM NC 27708 560532129 501(C)(3) 5418 GLOBAL HEALTH PROGRAMS ONA SYSTEMS INC 126 E 12TH ST SUITE 4A NEW YORK NY 100035320 383940780 OTHER 134412 GLOBAL HEALTH PROGRAMS OPENMRS INC 10425 COMMERCE DR STE 110 CARMEL IN 460327643 455316647 501(C)(3) 36768 GLOBAL HEALTH PROGRAMS PARSYL INC 3963 WALNUT STREET STE 200 DENVER CO 80205 814027966 OTHER 8500 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS PATHFINDER INTERNATIONAL 9 GALEN STREET SUITE 217 WATERTOWN MA 02472 530235320 501(C)(3) 116459 GLOBAL HEALTH PROGRAMS PHARMARON CPC INC 800 W BALTIMORE STREET 5TH FLOOR BALTIMORE MD 21201 208419781 OTHER 1321003 ESSENTIAL MEDICINE POPULATION COUNCIL ONE DAG HAMMERKJOLD PLAZA NEW YORK NY 10017 131687001 501(C)(3) 127341 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS POPULATION SERVICES INTERNATIONAL INC 1120 19TH ST NW STE 600 WASHINGTON DC 20036 560942853 501(C)(3) 268142 GLOBAL HEALTH PROGRAMS AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS REGENSTRIEF INSTITUTE INC 1101 W 10TH ST INDIANAPOLIS IN 46202 300007730 501(C)(3) 57528 GLOBAL HEALTH PROGRAMS ROSTROPOVICH-VISHNEVSKAYA FOUNDATION 1776 K STREET NW SUITE 700 WASHINGTON DC 20006 521752473 501(C)(3) 58486 ESSENTIAL MEDICINE SOLAR ELECTRIC LIGHT FUND 1612 K STREET NW SUITE 300 WASHINGTON DC 20006 521701564 501(C)(3) 39729 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS SYSTEMONE LLC 5 BRIDGE STREET SHELBURNE FALLS MA 01370 461066795 OTHER 86525 GLOBAL HEALTH PROGRAMS TECHCHANGE INC 2001 13TH ST NW 2ND FLOOR WASHINGTON DC 20009 273358772 OTHER 321300 GLOBAL HEALTH PROGRAMS THE ALBERT B SABIN VACCINE INSTITUTE INC 2175 K STREET NW SUITE 400 WASHINGTON DC 20037 061389829 501(C)(3) 50000 ESSENTIAL MEDICINE THE NATURE CONSERVANCY 4245 FAIRFAX DRIVE ARLINGTON VA 22203 530242652 501(C)(3) 18500 GLOBAL HEALTH PROGRAMS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO UCSF OFFICE OF SPONSORED RES 3333 CALIFORNIA ST STE 315 SAN FRANCISCO CA 94118 946036493 501(C)(3) 182685 GLOBAL HEALTH PROGRAMS AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS THE STATE UNIVERSITY OF NEW YORK 35 STATE STREET ALBANY NY 122072826 141368361 501(C)(3) 155082 ESSENTIAL MEDICINE TULANE UNIVERSITY 6823 ST CHARLES AVE NEW ORLEANS LA 70112 720423889 501(C)(3) 459580 ESSENTIAL MEDICINE AND GLOBAL HEALTH PROGRAMS UNIVERSITY OF ALABAMA GRANTS CONTRACTS ACCOUNTING AB 990 BIRMINGHAM AL 352940109 636005396 GOV 85011 ESSENTIAL MEDICINE UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH NORTH WORCESTER MA 01655 043167352 GOV 31089 TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR INFECTIOUS DISEASES CHAPEL HILL NC 275993368 566001393 501(C)(3) 137024 GLOBAL HEALTH PROGRAMS UNIVERSITY OF WASHINGTON GRANT CONTRACT ACCOUNTING 12455 COLLECTIONS DRIVE CHICAGO IL 60693 916001537 501(C)(3) 1542732 ESSENTIAL MEDICINE, GLOBAL HEALTH PROGRAMS, AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS VILLAGEREACH 2900 EASTLAKE AVE E SUITE 230 SEATTLE WA 981023012 912088484 501(C)(3) 256118 GLOBAL HEALTH PROGRAMS VITAL STRATEGIES INC 100 BROADWAY 4TH FLOOR NEW YORK NY 10005 223419667 501(C)(3) 9488 GLOBAL HEALTH PROGRAMS VITAL WAVE INC 555 BRYANT STREET 226 PALO ALTO CA 94301 203208079 OTHER 284978 GLOBAL HEALTH PROGRAMS WALTER REED ARMY INSTITUTE OF RESEARCH US TREASURY 503 ROBERT GRANT AVE SILVER SPRING MD 20910 520664528 GOV 2487368 ESSENTIAL MEDICINE WASHINGTON STATE UNIVERSITY 901 5TH AVE SUITE 2900 SEATTLE WA 98164 916001108 GOV 104777 GLOBAL HEALTH PROGRAMS PATH VACCINE SOLUTIONS 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 943384500 501(C)(3) 46272 ESSENTIAL MEDICINE, GLOBAL HEALTH PROGRAMS, AND MANAGEMENT 52 17 PART I, LINE 2: PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. X X 1 1 X X X X 0 0 0 0 0 0 0 1 0 NIKOLAJ JESTED GILBERT PRESIDENT AND CEO (FROM 1/2020) 183894 292691 0 0 72661 22694 9000 23249 11176 629 276731 339263 0 0 DAVID C KASLOW VP - ESSENTIAL MEDICNES 425987 0 0 0 1950 0 34200 0 35191 0 497328 0 0 0 TRAD M HATTON COUNTRY DIRECTOR 196161 0 0 0 180515 0 19167 0 35370 0 431213 0 0 0 JOHN O KONZ GLOBAL HEAD, FINANCIAL MANAGEMENT 346062 0 0 0 840 0 34200 0 32932 0 414034 0 0 0 DAVID W FLEMING VP - PUBLIC HEALTH 362605 0 0 0 1950 0 34200 0 10632 0 409387 0 0 0 JAMES B MCKENNA DEPUTY DIRECTOR 271132 0 0 0 50613 0 26023 0 58914 0 406682 0 0 0 ASHLEY J BIRKETT GLOBAL HEAD, MALARIA VACCINES 345577 0 0 0 1195 0 27138 0 29047 0 402957 0 0 0 BRUCE LAMONT INNIS GLOBAL HEAD, RESPIRATORY INFECTIONS 356827 0 0 0 910 0 32603 0 0 0 390340 0 0 0 JEFFREY D BERNSON VP - TECH, ANALYTICS, MRKT INNOV. 322366 0 0 0 375 0 32680 0 24513 0 379934 0 0 0 ELAINE L GIBBONS VP - GLOBAL ENGAGEMENT 289328 0 0 0 1950 0 33296 0 43428 0 368002 0 0 0 MOLLI M BARNES CHIEF PEOPLE OFFICER 278509 0 0 0 0 0 29341 0 22726 0 330576 0 0 0 JERRY KUO CHIEF OF STRATEGIC FINANCE 251067 0 0 0 1830 0 30616 0 27610 0 311123 0 0 0 BRIAN N NEVILLE CHIEF OF ACCOUNTING 258594 0 0 0 1920 0 27852 0 8974 0 297340 0 0 0 ERICA JANE SESSLE CHIEF OF STAFF 236865 0 0 0 1950 0 28554 0 26045 0 293414 0 0 0 PHILIPPE GUINOT CHIEF OF BUSINESS, FIN. & OPS. 0 251954 0 0 0 6077 0 21918 0 959 0 280908 0 0 SABRINA L POWERS GENERAL COUNSEL 232120 0 0 0 330 0 27838 0 9364 0 269652 0 0 0 STEPHEN B DAVIS PRESIDENT AND CEO (RESIGNED 1/2020) 50912 0 156629 0 41516 0 11120 0 2482 0 262659 0 0 0 PART I, LINE 1A HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT. PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). X 14 92087 FMV X SOFTWARE/SUPP. 5 668965 COST 0 0 1 0 PART I, COLUMN (B): THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: PATH IS A GLOBAL ORGANIZATION THAT WORKS TO ACCELERATE HEALTH EQUITY BY BRINGING TOGETHER PUBLIC INSTITUTIONS, BUSINESSES, SOCIAL ENTERPRISES, AND INVESTORS TO SOLVE THE WORLD'S MOST PRESSING HEALTH CHALLENGES. WITH EXPERTISE IN SCIENCE, HEALTH, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES UP SOLUTIONS-INCLUDING VACCINES, DRUGS, DEVICES, DIAGNOSTICS, AND INNOVATIVE APPROACHES TO STRENGTHENING HEALTH SYSTEMS WORLDWIDE. SINCE 2011, PATH AND OUR PARTNERS AND SUPPORTERS HAVE IMPROVED HEALTH FOR MORE THAN 150 MILLION PEOPLE ON AVERAGE EACH YEAR. FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: IN UKRAINE, PATH CONTINUED TO LEAD THE USAID-FUNDED SERVING LIFE PROJECT, WHICH REDUCES TB, HIV, AND HEPATITIS C VIRUS (HCV) TRANSMISSION IN THE PENAL SYSTEM AND COMMUNITIES ACROSS 12 REGIONS. RESPONDING TO COVID-19, WE OFFERED MULTIPLE OPTIONS FOR HIVST KIT DELIVERY AND ADVOCATED FOR VIRTUAL ART INITIATION AND MONITORING; WITHIN TWO MONTHS OF ENACTMENT OF A NEW POLICY, ALMOST 400 VIRTUAL CONSULTATIONS WERE HELD. IN ADDITION, WITH PATH'S TECHNICAL SUPPORT AND SUCCESSFUL ADVOCACY, THE MINISTRY OF JUSTICE PROCURED 60,000 HCV RAPID TESTS AND THE DRUGS REQUIRED TO TREAT NEARLY 500 PRISONERS WITH HCV. AS A PARTNER IN THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END TB PROJECT, PATH BEGAN A STUDY IN UKRAINE ON IMPLEMENTATION OF DIGITAL ADHERENCE TECHNOLOGIES (DATS) AND WORKED TO ESTABLISH A GLOBAL MARKET FOR DATS; FOR EXAMPLE, THE WISEPILL DIGITAL PILLBOX. BY THE END OF 2020, WISEPILL WAS THE FIRST-EVER DAT INCLUDED IN THE GLOBAL DRUG FACILITY CATALOGUE. PATH ALSO CONTINUED TO IMPLEMENT THE USAID-FUNDED SUPPORT TB CONTROL EFFORTS IN UKRAINE (STBCEU) PROJECT, WHICH FOCUSES ON PREVENTION, DETECTION, AND TREATMENT OF TB, DRUG-RESISTANT TB, AND TB/HIV. IN 2020, STBCEU RAPIDLY ADAPTED PROJECT ACTIVITIES TO A REMOTE MODEL. WE ALSO BEGAN SCALE-UP OF A SUCCESSFUL NEW APPROACH FOR TRANSPORTING DIAGNOSTIC SPECIMENS AND DELIVERING DRUGS TO TREAT TB AND HIV. WHEN USAID PROVIDED ADDITIONAL FUNDING FOR EMERGENCY RESPONSE TO COVID-19, PATH PROCURED DNA EXTRACTORS AND CONDUCTED ON-THE-JOB TRAINING TO DRAMATICALLY INCREASE THE NUMBER OF SAMPLES FOR COVID-19 (AND OTHER DISEASES) THAT COULD BE TESTED IN A DAY. THE NUMBER OF UNPROCESSED SAMPLES AT ONE LABORATORY WENT FROM 800 TO ZERO IN LESS THAN A MONTH AND REMAINED AT ZERO THROUGH THE END OF 2020. IN INDIA, PATH ENHANCED HIV SERVICE DELIVERY THROUGH AUTOMATION OF DATA AND DEVELOPMENT OF A MACHINE-LEARNING-ENABLED TOOL TO REDUCE LOSS OF PATIENTS FROM TREATMENT. TO IMPROVE TB SERVICES, WE PILOTED ARTIFICIAL INTELLIGENCE TO STREAMLINE CHEST X-RAY READINGS, ENABLING QUICKER DIAGNOSIS AND INITIATION ON TREATMENT. IN TAJIKISTAN, KAZAKHSTAN, AND UZBEKISTAN, PATH DEVELOPED DRUG-RESISTANT TB CASE MANAGEMENT GUIDELINES, SET UP A DIGITAL TB PREVENTION PLATFORM, PROVIDED TECHNICAL EXPERTISE ON LATENT TB INFECTION, AND MORE FOR THE USAID ELIMINATING TB IN CENTRAL ASIA PROJECT. IN TANZANIA, THE USAID-FUNDED INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT SUPPORTED KEY FUNCTIONS AT THE CENTRAL TB REFERENCE LABORATORY, FACILITATED REPORTING FROM GENEXPERT TESTING SITES, AND ASSESSED THE TB DIAGNOSTIC NETWORK. IN VIETNAM, PATH CONTINUED TO PIONEER DIFFERENTIATED AND INTEGRATED SERVICE DELIVERY THROUGH THE USAID HEALTHY MARKETS PROJECT. IN 2020, HEALTHY MARKETS ADDED NEW MODES OF DELIVERY FOR PRE-EXPOSURE PROPHYLAXIS AND HIVST. THE PROJECT ALSO CREATED ONE-STOP SHOPS OFFERING PREVENTION, TESTING, AND TREATMENT FOR HIV AND SEXUALLY TRANSMITTED INFECTIONS; MENTAL HEALTH SCREENING AND REFERRALS; GENDER-AFFIRMING SERVICES; AND HEPATITIS B AND C SCREENING AND TREATMENT FOR PLHIV. THE PROJECT USED SOCIAL MEDIA, WEBSITES, AND TELEPHONE HOTLINES TO PROMOTE AND SUPPORT THESE SERVICES AND RAISE AWARENESS OF COVID-19. THESE ADAPTATIONS WERE CRITICAL TO NOT ONLY CONTINUING BUT ACTUALLY INCREASING SERVICES DURING THE PANDEMIC; FOR EXAMPLE, THE PROJECT'S ONLINE HIVST 3.0 ORDERING PLATFORM AND HOME DELIVERY RESULTED IN A 93 PERCENT INCREASE IN THE NUMBER OF HIVST KITS DISTRIBUTED TO KEY POPULATIONS. THROUGH THE IDDS PROJECT IN VIETNAM, PATH CONTINUED TO SUPPORT THE NATIONAL TUBERCULOSIS PROGRAM (NTP). IDDS ASSESSED PROGRESS ON THE "DOUBLE X" STRATEGY (CHEST X-RAY AND GENEXPERT TEST) AND PUT FORTH EVIDENCE-BASED RECOMMENDATIONS TO IMPROVE IMPLEMENTATION. THE BREATH FOR LIFE (B4L) PROJECT 2.0 IN VIETNAM IMPROVED AND SCALED UP THE B4L MODEL DEVELOPED IN PRIOR YEARS. B4L 2.0 INCREASED ACCURATE DIAGNOSIS OF PEDIATRIC TB, TREATMENT OF TB AND LATENT TB, AND TB PREVENTION. FOLLOWING A STOOL-BASED GENEXPERT TESTING PILOT, B4L 2.0 AND IDDS PAIRED UP TO SUPPORT THE NTP IN THE USE OF STOOL SAMPLES TO INCREASE TB DETECTION AMONG CHILDREN. IMPORTANTLY, THE VIETNAM NTP INCLUDED PEDIATRIC TB ACTIVITIES INFORMED BY B4L IN ITS STRATEGIC PLAN 2021-2025. IN ZAMBIA, PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED ERADICATE TB PROJECT, WHICH TESTED NEARLY 150,000 PEOPLE AND DIAGNOSED APPROXIMATELY 21,000 WITH TB. OF THE NEARLY 9,000 BACTERIOLOGICALLY CONFIRMED INDIVIDUALS, 95 PERCENT WERE INITIATED ON TREATMENT. TO MITIGATE COVID-19, THE PROJECT CONDUCTED INFECTION PREVENTION AND CONTROL TRAININGS FOR MORE THAN 500 HEALTH CARE WORKERS, COMPLETED FOLLOW-UP FACILITY ASSESSMENTS, ACTIVATED THREE TESTING SITES, AND ORIENTED 500 COMMUNITY-BASED VOLUNTEERS. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION (MNCHN) IS PART OF PATH'S COMPREHENSIVE, ONE HEALTH, PEOPLE- AND COMMUNITY-CENTERED PRIMARY HEALTH CARE MODEL, WHICH ADDRESSES BROADER DETERMINANTS OF HEALTH (E.G., SOCIAL, ECONOMIC, ENVIRONMENTAL). WE FOCUS ON INNOVATIVE, EVIDENCE-BASED TOOLS AND APPROACHES TO MEET PEOPLE'S NEEDS AND PREFERENCES ACROSS THEIR LIFETIME. TOGETHER WITH PARTNERS AROUND THE WORLD, WE DEVELOP, ADAPT, AND SCALE UP TECHNOLOGIES AND SYSTEMS TO REDUCE ILLNESS AND DEATH AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. IN 2020, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD); FOR INSTANCE, WITH PATH SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, AND MOZAMBIQUE CONTINUED TO INCORPORATE ECD SERVICES INTO BASIC HEALTH CARE. THIS PIONEERING WORK CENTERS AROUND BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE STRENGTHENING THE CAPACITY OF HEALTH SYSTEMS AND HEALTH SERVICE PROVIDERS. ALONG WITH WHO, UNICEF, THE WORLD BANK, AND OTHERS, PATH PROMOTED THE NURTURING CARE FOR ECD FRAMEWORK-A STRUCTURE FOR COUNTRIES TO ADOPT, ADAPT, AND SCALE UP ECD SERVICES. TO ENSURE THAT ALL INFANTS HAVE ACCESS TO HUMAN MILK, PATH FOCUSES ON BREASTFEEDING PROMOTION, INCLUDING PROVISION OF SAFE DONOR MILK THROUGH LOCAL HUMAN MILK BANKS. IN 2020, WE CONTINUED TO ADVOCATE FOR UPTAKE AND USE OF GLOBAL STANDARDS FOR STRENGTHENING HUMAN MILK BANKING. WE ALSO BEGAN CO-DEVELOPING A DIGITAL KIT TO OPTIMIZE NEWBORN FEEDING AND THE PROVISION OF LACTATION SUPPORT. IN GHANA, PATH IS LEADING A FOUR-YEAR (2020-2024) INITIATIVE, ADVANCED NEWBORN CARE IN GHANA: BEYOND MAKING EVERY BABY COUNT INITIATIVE (MEBCI 2.0), TO REDUCE PERINATAL MORTALITY IN FOUR HIGH-VOLUME REFERRAL HOSPITALS. IN 2020, MEBCI 2.0 ENGAGED WITH THE GHANA HEALTH SERVICE TO DESIGN ITS NEWBORN ACTION PLAN, MOBILIZE REGIONAL STAKEHOLDERS AND RESOURCES, AND DRIVE ADVOCACY AND POLICY ACTION. IN FOUR FOCUS COUNTRIES, PATH EMBARKED ON LESSONS LEARNED IN ESTABLISHING IN-PATIENT NEWBORN CARE, A PLATFORM FOR UNDERSTANDING AND SHOWCASING COUNTRY-LEVEL JOURNEYS TO PROVIDING CRITICAL CARE FOR SMALL AND SICK NEWBORNS. PATH ALSO LED THE ASSET TRACKER PROJECT TO DOCUMENT UPTAKE OF 14 KEY MNCHN ASSETS IN 81 COUNTDOWN TO 2030 COUNTRIES ACROSS AFRICA AND SOUTH ASIA. THROUGH KEY INFORMANT INTERVIEWS AND POLICY REVIEWS IN SEVEN TARGET COUNTRIES, PATH IDENTIFIED BARRIERS AND ENABLERS TO SCALE-UP AND PRESENTED AN INTERACTIVE DASHBOARD TO GUIDE STRATEGIES TO ACCELERATE COVERAGE. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM DRIVES NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. IN 2020, PATH COMPLETED A SEVEN-YEAR PROJECT, MAXIMISING THE QUALITY OF SCALING UP NUTRITION PLUS (MQSUN+), WHICH ENGAGED MORE THAN 50 COUNTRIES AND THE GLOBAL SUN MOVEMENT SECRETARIAT IN DEMAND-DRIVEN, ADAPTIVE COLLABORATIONS. MQSUN+ EMPHASIZED COUNTRY-LED MULTISECTOR PLANNING, OFTEN IN FRAGILE CONTEXTS. IN THE LAST YEAR, SIX MQSUN+ COUNTRIES PRODUCED ENDORSED, COSTED PLANS TO REDUCE FOOD INSECURITY AND IMPROVE NUTRITION. OTHER ACTIVITIES IN 2020 INCLUDED PARTNERING WITH THE NATURE CONSERVANCY, DUKE UNIVERSITY, AND THE INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE ON USE OF ALTERNATIVE PROTEINS. WE ALSO PARTNERED WITH HARVESTPLUS TO EXPAND THE REACH OF BIOFORTIFIED CROPS. PATH CONTINUED OUR WORK ON THE BRIDGE COLLABORATIVE, A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT OF MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS TO ADDRESS HUMAN AND PLANETARY HEALTH. IN CONJUNCTION WITH THE WILDLIFE CONSERVATION SOCIETY AND THE NATURE CONSERVANCY, THE BRIDGE COLLABORATIVE FOCUSED ATTENTION ON FOOD SYSTEMS AND THE INTERSECTION OF HUMAN AND PLANETARY HEALTH. FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: IN 2020, MNCHN STAFF SERVED GLOBALLY IN LEADERSHIP ROLES RELATED TO COVID-19 AND THE PROTECTION OF WOMEN AND CHILDREN. WE PRESENTED (MOSTLY VIRTUALLY) AT KEY GLOBAL AND NATIONAL MEETINGS AND AUTHORED AND CONTRIBUTED TO HIGH-PROFILE PEER-REVIEWED JOURNAL ARTICLES, BOOK CHAPTERS, GLOBAL REPORTS, AND SYSTEMATIC REVIEWS. THESE EFFORTS ADVANCED THINKING ON BROAD, EFFECTIVE SOLUTIONS TO THE MOST PRESSING CHALLENGES IN MNCHN. SEXUAL AND REPRODUCTIVE HEALTH PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH (SRH) IS GUIDED BY THE KEY PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL PEOPLE. AND BECAUSE WE UNDERSTAND THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF WOMEN'S REPRODUCTIVE HEALTH, WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE BEST SUITED TO ADDRESS THEIR DIVERSE NEEDS AND CIRCUMSTANCES. WE SPECIALIZE IN REDUCING BARRIERS TO ACCESS AND INTRODUCING WOMAN-INITIATED PRODUCTS. PATH CHAMPIONS PEOPLE'S RIGHT TO MANAGE THEIR OWN SRH BY CREATING AND ADVANCING IMPROVED TOOLS AND PRACTICES THAT MAKE SELF-CARE FOR SRH POSSIBLE. IN 2020, WE CO-CREATED WITH THE GOVERNMENTS OF NIGERIA, SENEGAL, AND UGANDA THEIR FIRST-EVER NATIONAL SELF-CARE GUIDELINES. OUR INTEGRATED APPROACH INCLUDES ATTENTION TO CONTRACEPTION, CERVICAL AND BREAST CANCER, SEXUALLY TRANSMITTED INFECTIONS, AND A WOMAN'S RIGHT TO DECIDE WHETHER AND WHEN TO BECOME A MOTHER. OUR EFFORTS TO EXPAND ACCESS TO THE SELF-INJECTABLE CONTRACEPTIVE SUBCUTANEOUS DMPA (DMPA-SC, OR SAYANA PRESS) CONTINUED IN 2020. THE DMPA-SC ACCESS COLLABORATIVE WORKED WITH MINISTRIES OF HEALTH AND MULTISECTOR PARTNERS IN SIX COUNTRIES TO FACILITATE SELF-INJECTION INTRODUCTION AND SCALE-UP PLANNING FOR A RANGE OF CONTRACEPTIVES. DATA FROM 11 COUNTRIES SHOWED NEARLY 300,000 CLIENT VISITS FOR CONTRACEPTIVE SELF-INJECTION IN 2020; THE ACCESS COLLABORATIVE ALSO LAUNCHED AND SUPPORTED A CADRE OF "SELF-INJECTION AMBASSADORS" TO ADVANCE CONTRACEPTIVE SELF-INJECTION AND SELF-CARE OPTIONS MORE BROADLY. PATH ALSO WORKED TO IMPROVE THE PREVENTION, DETECTION, AND TREATMENT OF CERVICAL PRECANCER CAUSED BY INFECTION WITH HUMAN PAPILLOMAVIRUS (HPV). WE CONTINUED OUR PARTNERSHIP WITH THE MINISTRIES OF HEALTH IN GUATEMALA, HONDURAS, AND NICARAGUA TO SCALE UP HPV TESTING IN THE PUBLIC SECTOR. WE ALSO EVALUATED FOLLOW-UP AND TREATMENT STRATEGIES TO ENSURE WOMEN RECEIVE APPROPRIATE, COMPREHENSIVE CARE. AS THE PROJECT NEARED CLOSEOUT, WE WORKED TO TRANSITION ACTIVITIES TO THE MINISTRIES. GLOBALLY, PATH HELPED SHAPE STRATEGIES FOR LOW- AND MIDDLE-INCOME COUNTRIES AS PART OF WHO'S CALL FOR GLOBAL CERVICAL CANCER ELIMINATION. IN PERU, PATH CONTINUED TO IMPLEMENT A MODEL FOR EARLY DETECTION OF BREAST CANCER APPROPRIATE AND FEASIBLE FOR LOW- AND MIDDLE-RESOURCE SETTINGS. WE PARTNERED WITH THE MOH TO DESIGN AND IMPLEMENT A REAL-TIME DIGITAL PATIENT TRACKING SYSTEM FOR BREAST CANCER DETECTION. IN MYANMAR, PATH SUPPORTED THE CREATION OF THE NATIONAL STRATEGIC PLAN FOR REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH; DRAFTED A NATIONAL OPERATIONAL PLAN FOR CERVICAL PRECANCER SCREENING AND TREATMENT; CREATED A TRAINING CURRICULUM FOR HEALTH WORKERS ON SEXUAL AND REPRODUCTIVE HEALTH AND RIGHTS (SRHR), INCLUDING SELF-CARE INTERVENTIONS; HELD ADVOCACY WORKSHOPS; DEVELOPED SRHR AWARENESS TOOLKITS FOR PEOPLE LIVING WITH DISABILITIES; AND RESPONDED TO COVID-19 BY PARTNERING WITH LOCAL CIVIL-SOCIETY ORGANIZATIONS TO DISTRIBUTE INFECTION PREVENTION INFORMATION AND SUPPLIES IN REFUGEE CAMPS AND HARD-TO-REACH AREAS OF TWO STATES. IN INDIA, WE WORKED WITH THE ODISHA STATE GOVERNMENT TO LEVERAGE THE NATION'S POSTAL SERVICE TO DELIVER CONTRACEPTIVES BY MAIL-AND SO MAINTAIN ACCESS THROUGHOUT COVID-19. PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 540 PUBLIC AND PRIVATE ENTITIES AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO CRITICAL SRH AND FAMILY PLANNING SUPPLIES AND SERVICES. NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF THE FIGHT AGAINST NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES AND CARDIOVASCULAR DISEASE, IN LOW-RESOURCE SETTINGS WORLDWIDE, WHERE THE BURDEN OF THESE DISEASES IS RISING DISPROPORTIONATELY. IN 2020, PATH CONTINUED TO SERVE AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES AND PRODUCTS. THIS GLOBAL, MULTISECTORAL COLLABORATION WORKS TO INCREASE ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LOW- AND MIDDLE-INCOME COUNTRIES. IN ADDITION TO GLOBAL ADVOCACY, THE COALITION LED THE DEVELOPMENT OF A FORECASTING TOOL FOR NCD MEDICINES AND PRODUCTS, PILOTED THE TOOL IN KENYA, AND LAID THE GROUNDWORK FOR ITS INTRODUCTION IN UGANDA. PATH IMPLEMENTED NCD PROJECTS IN GHANA, KENYA, AND VIETNAM THAT BUILD STRONGER PRIMARY HEALTH CARE SYSTEMS, SUPPLY CHAINS, AND DATA-DRIVEN DECISION-MAKING-ALL CRITICAL COMPONENTS OF HEALTH SYSTEM RESILIENCY: OUR EFFORTS IN GHANA INCLUDED SUPPLY CHAIN STRENGTHENING, MESSAGING TO SUPPORT THE COVID-19 RESPONSE, AND INTRODUCTION OF THE NCD NAVIGATOR-A FIRST-OF-ITS-KIND, LOCALLY MANAGED, NCD DIGITAL INFORMATION SYSTEM FOR RESOURCE PLANNING AND ALLOCATION. IN PARTNERSHIP WITH THE GHANA HEALTH SERVICE, PATH'S HEALTHY HEART AFRICA PROJECT CONDUCTED MORE THAN 500,000 BLOOD PRESSURE SCREENINGS AND LINKED THOSE DIAGNOSED TO TREATMENT. IN KENYA, PATH DEPLOYED A CUTTING-EDGE PROGRAM THAT ENABLES COMMUNITY AND HOUSEHOLD SCREENINGS FOR HYPERTENSION, REMOTE BLOOD PRESSURE AND BLOOD SUGAR MONITORING, TELEMEDICINE, COMMUNITY-BASED DRUG DELIVERY, AND ENHANCED DATA MANAGEMENT. WE TRAINED 2,815 HEALTH CARE WORKERS ON COVID-19 INFECTION PREVENTION AND CONTROL, WITH AN EMPHASIS ON PEOPLE LIVING WITH NCDS. AS THE MOH SEEKS TO IMPROVE THE NCD SUPPLY CHAIN IN PREPARATION FOR UNIVERSAL HEALTH COVERAGE, WE TRANSITIONED OWNERSHIP OF THE NCD NAVIGATOR TO THE MOH AND FINALIZED OUR KENYA NCD SUPPLY CHAIN REPORT. RECOMMENDATIONS FROM THE REPORT WERE ADOPTED IN THE KENYA NCD STRATEGY 2021-2025. OUR FOCUS IN VIETNAM WAS ON A PRIMARY HEALTH CARE MODEL THAT USES PUBLIC-PRIVATE PARTNERSHIPS, DIGITAL TOOLS, AND COMMUNITY HEALTH WORKERS TO SUPPORT SCREENING AND LINKAGES TO CARE; FOR EXAMPLE, WE BROKERED A PARTNERSHIP BETWEEN THE MOH, CO.OPMART (A LARGE, PRIVATE-SECTOR SUPERMARKET CHAIN), AND PATH TO LAUNCH THE FIRST-EVER SUPERMARKET BLOOD PRESSURE CHECKPOINT IN HO CHI MINH CITY. THE CHECKPOINT SCREENED ALMOST 1,000 PEOPLE BY THE END OF 2020, DEMONSTRATING THE FEASIBILITY OF THE APPROACH. FINALLY, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO NCD PREVENTION AND CARE. HEALTH SYSTEMS INNOVATION AND DELIVERY PATH'S HEALTH SYSTEMS INNOVATION AND DELIVERY (HSID) PROGRAM STRENGTHENS HEALTH SYSTEMS AND ENHANCES COUNTRY CAPACITY FOR DATA-DRIVEN DECISION-MAKING. OUR PORTFOLIO SERVES AS AN ORGANIZING MECHANISM FOR PATH PROJECTS AND INITIATIVES THAT STRENGTHEN HEALTH SYSTEMS. HSID'S HEALTH SYSTEMS ANALYTICS UNIT PROMOTES SYSTEMS THINKING. WITHIN AND OUTSIDE OF PATH, THE UNIT LEADS COMPLEX EVALUATIONS OF HEALTH PROGRAMS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES HEALTH TECHNOLOGY INTRODUCTION AND SCALE-UP, AND IMPROVES DATA QUALITY AND USE FOR DECISION-MAKING. IN 2020, AS PART OF THE GLOBAL FUND'S PROSPECTIVE COUNTRY EVALUATIONS, THE UNIT EVALUATED THE GLOBAL FUND'S BUSINESS MODEL IN THE DRC, GUATEMALA, SENEGAL, AND UGANDA-EXAMINING BARRIERS AND FACILITATORS TO IMPACT. THE GLOBAL HEALTH SECURITY TEAM CONTINUED TO INNOVATE FOR THE PREVENTION, DETECTION, AND CONTROL OF INFECTIOUS DISEASE OUTBREAKS. WITH SUPPORT FROM THE US CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), THE TEAM WORKED WITH NATIONAL LEADERS IN THE DRC, SENEGAL, TANZANIA, AND VIETNAM TO BUILD THEIR CAPACITY FOR EPIDEMIC PREPAREDNESS AND RESPONSE. THE TEAM ALSO WORKED AS A MAJOR SUBGRANTEE ON THE USAID IDDS PROJECT. OUR CROSS-ORGANIZATIONAL IMPACT TEAM FOR EPIDEMIC PREPAREDNESS AND RESPONSE REMAINED AT THE FOREFRONT OF THE EBOLA RESPONSE IN THE DRC-ENHANCING SURVEILLANCE, DETECTION, AND RESOURCE MOBILIZATION. OTHER EFFORTS INCLUDED STRENGTHENING ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING DIAGNOSTIC NETWORK CAPABILITIES, AND LINKING THIS WORK WITH DEVELOPMENT OF NEW DIAGNOSTICS, VACCINES, AND DATA TOOLS. COUNTRY PROGRAMS PATH'S COUNTRY PROGRAMS SUPPORT WORK RANGING FROM SMALL-SCALE PILOTS TO LARGE, MULTI-COUNTRY EFFORTS. IN 2020, WE OPERATED FULL-SCALE "COUNTRY" OFFICES IN THE DRC, CHINA, ETHIOPIA, INDIA, KENYA, MYANMAR, SENEGAL, TANZANIA, UGANDA, UKRAINE, VIETNAM, AND ZAMBIA, AS WELL AS SMALLER "PROJECT" OFFICES IN MANY OTHER COUNTRIES. OUR EXAMPLES THIS YEAR FOCUS ON INDIA, UGANDA, AND VIETNAM. FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: INDIA: PATH HAS WORKED IN INDIA FOR MORE THAN 20 YEARS TO IMPROVE HEALTH AND SAVE LIVES THROUGH INNOVATION AND COLLABORATION WITH LOCAL PARTNERS. PATH'S PROJECTS IN INDIA FOCUS ON TB, HIV, NEGLECTED TROPICAL DISEASES, VACCINES (BOTH DEVELOPMENT AND DELIVERY), AND REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH. IN 2020, PATH PROVIDED TECHNICAL SUPPORT TO THE GOVERNMENT OF INDIA TO EXPAND OUR AWARD-WINNING PUBLIC-PRIVATE MODEL FOR TB DIAGNOSIS AND TREATMENT TO 15 STATES ACROSS THE COUNTRY. OUR PIONEERING WORK IN RICE FORTIFICATION CONTINUED AS WELL, BRINGING LIFESAVING NUTRITION TO NEARLY 1 MILLION PEOPLE, INCLUDING MORE THAN 650,000 SCHOOLCHILDREN. WITH THE ONSET OF COVID-19, PATH IMMEDIATELY LEVERAGED OUR PROGRAMMATIC EXPERTISE AND WORKING RELATIONSHIPS WITH THE GOVERNMENT TO PREPARE HEALTH FACILITIES TO RESPOND TO THE DISEASE. WITH FUNDING FROM THE ROCKEFELLER FOUNDATION, PATH AND OUR PARTNERS WORKED WITH THE STATE GOVERNMENTS OF MAHARASHTRA AND PUNJAB TO IMPROVE ACCESS TO HIGH-QUALITY, AFFORDABLE TESTING FOR COVID-19 BY IMPLEMENTING NEWER DIAGNOSTIC TECHNOLOGIES AND NOVEL TESTING ALGORITHMS, AUTOMATING DATA ENTRY AND ANALYSIS, AND INCREASING HUMAN RESOURCE CAPACITY IN LABORATORIES. WE ALSO BEGAN IMPLEMENTING DECENTRALIZED GENE SEQUENCING PLATFORMS AT THE STATE LEVEL TO ACCELERATE IDENTIFICATION OF NEW VIRAL MUTATIONS AND VARIANTS. PATH'S INDIA TEAM IN 2020 CONTINUED OUR COLLABORATION WITH OTHER SOUTH ASIAN COUNTRIES; FOR EXAMPLE, WE SUPPORTED DEVELOPMENT OF A POINT-OF-CARE "SUITCASE LABORATORY" BASED ON RECOMBINASE POLYMERASE AMPLIFICATION FOR RAPID AND ACCURATE DIAGNOSIS OF KALA-AZAR AND POST-KALA-AZAR DERMAL LEISHMANIASIS IN BANGLADESH AND NEPAL. UGANDA: PATH'S UGANDA COUNTRY PROGRAM HAS BEEN PARTNERING CLOSELY WITH THE UGANDA MOH FOR MORE THAN 15 YEARS, IMPLEMENTING AN EVER-WIDER RANGE OF PROJECTS AIMED AT IMPROVING HEALTH. BELOW ARE A FEW HIGHLIGHTS FROM 2020. AS THE IDDS PROJECT LEAD IN UGANDA, PATH WORKED WITH THE UGANDA GOVERNMENT TO REVIEW EXISTING SURVEILLANCE SYSTEMS IN HUMAN AND ANIMAL HEALTH; SUPPORTED DEVELOPMENT OF NEW TESTING ALGORITHMS FOR PRIORITY ZOONOTIC DISEASES; DEVELOPED A STANDARDIZED QUALITY-CONTROL TOOLKIT; ASSESSED ANIMAL AND HUMAN SPECIMEN REFERRAL SYSTEMS; AND SUPPORTED LABORATORY TRAININGS. PATH'S LARGEST ADVOCACY AND PUBLIC POLICY PROJECT-OPERATING WORLDWIDE AND FUNDED BY THE BILL & MELINDA GATES FOUNDATION-CONTINUED TO FOCUS IN UGANDA ON IMMUNIZATION, PRIMARY HEALTH CARE, AND REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH. WITH COVID-19 DISRUPTING HEALTH SYSTEMS, PATH SUPPORTED THE MOH TO DEVELOP AND BROADLY DISSEMINATE MESSAGES ON COVID-19 PREVENTION AND THE CONTINUITY OF ESSENTIAL HEALTH SERVICES. PATH ALSO HELPED DRAFT THE UGANDA EXPANDED PROGRAM ON IMMUNIZATION RECOVERY PLAN FOR IMMUNIZATION SERVICES DURING COVID-19. OUR ADVOCACY FOR MEDICAL OXYGEN SCALE-UP IN UGANDA, LAUNCHED PRE-COVID-19, GAINED ADDED TRACTION IN THE PANDEMIC. PATH WORKED WITH THE KAMPALA CITY AUTHORITY AND TWO LEADING TELEVISION STATIONS TO AMPLIFY COVID-19 INFECTION PREVENTION AND CONTROL (IPC) MESSAGES; WE RECORDED A TALK SHOW THAT WAS HIGHLY PROMOTED AND FEATURED ON ONE OF THE TELEVISION STATIONS' TWITTER ACCOUNTS, WITH 1.2 MILLION FOLLOWERS. WITH FUNDING FROM THE HILTON FOUNDATION, PATH INTRODUCED ONSITE CHLORINE GENERATION FOR IPC AT HEALTH FACILITIES AND DONATED PERSONAL PROTECTIVE EQUIPMENT AND IPC MATERIALS TO 48 FACILITIES IN 11 DISTRICTS. WE PARTICIPATED IN A WATER FOR PEOPLE WORKING GROUP WITH INTERNATIONAL RESCUE COMMITTEE, WORLD VISION, AND THE US CDC TO IMPROVE WATER, SANITATION, AND HYGIENE IN HEALTH FACILITIES. AS PART OF A SUPPLY SYSTEMS INNOVATIONS GRANT, PATH COORDINATED THE SUCCESSFUL DISTRIBUTION AND INSTALLATION OF UPDATED COLD CHAIN EQUIPMENT IN TEN REGIONS OF UGANDA AND WORKED WITH THE MOH ON HPV VACCINE ACCESS AND COVERAGE. WE SUPPORTED WHO'S EFFECTIVE VACCINE MANAGEMENT INITIATIVE TO REVIEW STOCK STATUS, FORECASTING, COLD CHAIN EQUIPMENT MAINTENANCE, AND LOGISTICS PLANNING FOR COVID-19 AND OTHER VACCINES. TO PREPARE FOR COVID-19 VACCINE INTRODUCTION, PATH (WITH SUPPORT FROM GAVI, THE VACCINE ALLIANCE) DEVELOPED AN ADVOCACY AND ENGAGEMENT PLAN TO INCREASE STAKEHOLDER BUY-IN AND COMMUNITY ACCEPTANCE. WE THEN SUPPORTED THE SUCCESSFUL NATIONAL VACCINATION LAUNCH. THE BILL & MELINDA GATES FOUNDATION FAMILY PLANNING PROJECT AIMS TO IMPROVE THE HEALTH OF WOMEN AND GIRLS BY EXPANDING ACCESS TO RIGHTS-BASED FAMILY PLANNING, INCLUDING DMPA-SC, AN INJECTABLE CONTRACEPTIVE. IN UGANDA, PATH MOBILIZED FUNDING THAT LED TO THE CONTINUATION AND EVEN ACCELERATION OF FAMILY PLANNING EFFORTS, DESPITE CHALLENGES RELATED TO COVID-19. PATH WORKED WITH PARTNERS TO ENSURE DMPA-SC (INCLUDING SELF-INJECTION, WHERE APPROVED) WAS ACCEPTABLE TO USERS AND AVAILABLE AT AN AFFORDABLE PRICE AND AT A VARIETY OF SERVICE DELIVERY POINTS. FINALLY, THE HIV SELF-TESTING AFRICA (STAR) INITIATIVE (PHASE III) WORKED TO ESTABLISH THE STRUCTURES, SYSTEMS, AND OVERSIGHT NECESSARY FOR LONG-TERM SUSTAINABILITY OF THE HIVST MARKET IN UGANDA. COLLABORATING WITH THE MOH AND OTHER STAKEHOLDERS, THE STAR III TEAM DEVELOPED A FOUR-YEAR NATIONAL SCALE-UP PLAN FOR HIVST (2021-2024) AND MOBILIZED AND SUPPORTED A WHO PREQUALIFICATION TRAINING. THE TEAM MAPPED HIVST PARTNERS, TRAINED PEERS AND PROVIDERS, ASSESSED CURRENT REGULATIONS AND POLICIES, AND WORKING WITH THE NATIONAL DRUG AUTHORITY, DEVELOPED A POST-MARKET SURVEILLANCE PLAN. THE PROJECT REACHED NEARLY 16,000 CLIENTS, MAINLY THROUGH COMMUNITY DISTRIBUTION. VIETNAM: IN 2020, PATH CELEBRATED OUR 40TH ANNIVERSARY IN VIETNAM. THROUGH THE GLOBAL HEALTH SECURITY PARTNERSHIP FUNDED BY THE US CDC, PATH UPGRADED THE MOH'S ONLINE INFECTION SURVEILLANCE PORTAL, LAUNCHED A NEW ANTIMICROBIAL RESISTANCE (AMR) PORTAL, SUPPORTED DEVELOPMENT OF COVID-19 TRACKING AND SENTINEL SURVEILLANCE SYSTEMS, AND SUPPORTED TWO HOSPITALS IN QUALITY IMPROVEMENT IMPLEMENTATION. PATH ALSO ASSESSED VIETNAM'S ANIMAL HEALTH INFORMATION SYSTEM AS WELL AS THE LABORATORY CAPACITY, SPECIMEN REFERRAL, AND SURVEILLANCE SYSTEMS FOR ANIMAL AND HUMAN HEALTH. THROUGH THE FLEMING FUND, WE HELPED STRENGTHEN LABORATORY INFORMATION SYSTEMS AND BIOREPOSITORY MANAGEMENT, SUPPORTED HOSPITALS TO SUBMIT AMR REPORTS, DEVELOPED THE DEPARTMENT OF ANIMAL HEALTH'S AMR E-REPORTING PORTAL, AND ORGANIZED A WHONET WORKSHOP FOR THE DEPARTMENT AND THREE ANIMAL LABORATORIES. FOR COVID-19, PATH AND THE US CDC CONTRIBUTED TO THE NATIONAL GUIDELINES, DEVELOPED AN ONLINE SELF-ASSESSMENT FORM, AND SUPPORTED TRAINING FOR HOSPITALS AND 3,300 HEALTH CARE PROVIDERS. PATH ASSISTED THE MOH WITH COVID-19 VACCINE DEVELOPMENT AND INTRODUCTION EFFORTS AND SUPPORTED THE INTERNATIONAL VACCINE ACCESS CENTER TO PRODUCE COVID-19 VACCINE LOTS FOR USE IN CLINICAL TRIALS. THE USAID HEALTHY MARKETS PROJECT SCALED UP ACCESS TO HIVST AND HIV PREVENTION SERVICES, ENROLLING 6,177 NEW CLIENTS IN PRE-EXPOSURE PROPHYLAXIS AND REACHING MORE THAN 40,700 WITH HIV TESTING. PATH SUPPORTED A $2.5M+ PRIVATE-SECTOR INVESTMENT IN HIV RESPONSE AND BUILT THE CAPACITY AND SUSTAINABILITY OF KEY POPULATION ORGANIZATIONS. PATH ALSO SUPPORTED THE NATIONAL TB PROGRAM TO PILOT STOOL-BASED DIAGNOSIS OF PEDIATRIC TB AND CONSEQUENTLY UPDATE THE NATIONAL PEDIATRIC TB GUIDELINES. (SEE ALSO THE HIV AND TUBERCULOSIS SECTION.) THE INTRODUCING DIGITAL IMMUNIZATION INFORMATION SYSTEMS-EXCHANGE AND LEARNING PROJECT, FUNDED BY THE BILL & MELINDA GATES FOUNDATION, LAUNCHED AN E-LEARNING PLATFORM AND E-IMMUNIZATION CARD SYSTEM IN HANOI AND SON LA AND HELPED THE NATIONAL EXPANDED PROGRAM ON IMMUNIZATION TRANSITION TO PAPERLESS IN FOUR PROVINCES. FINALLY, TO COMBAT MALARIA, PATH CONDUCTED OPERATIONAL RESEARCH IN VIETNAM THAT PROVIDED EVIDENCE FOR ADOPTION OF G6PD TESTING. FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE: WORK CONTINUED ON THE DATA USE PARTNERSHIP (DUP), WHICH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE ITS HEALTH INFORMATION SYSTEMS. IN 2020, DUP REFRESHED THE TANZANIA DIGITAL HEALTH INVESTMENT ROAD MAP AND RECEIVED APPROVAL FOR THE COUNTRY'S NEW CENTRE FOR DIGITAL HEALTH. DUP ALSO FINALIZED THE TANZANIA HEALTH ENTERPRISE ARCHITECTURE, A BLUEPRINT FOR IDENTIFYING AND ALIGNING IMPORTANT INTERRELATIONSHIPS BETWEEN THE COUNTRY'S DIGITAL SYSTEMS TO AVOID FRAGMENTATION, DUPLICATION, AND LACK OF INTEROPERABILITY. PATH BEGAN A NEW PROJECT, DATA USE ACCELERATION AND LEARNING, TO DOCUMENT AND AMPLIFY LEARNINGS FROM FIVE FOCAL COUNTRIES DIGITALIZING THEIR HEALTH SYSTEMS. THE INFORMATION WILL SUPPORT GOVERNMENTS, IMPLEMENTERS, POLICYMAKERS, AND FUNDERS AS THEY SHIFT THEIR FINANCING, GUIDANCE, AND PROGRAMMATIC APPROACHES TO IMPROVE THE USE OF DATA. PATH ALSO LAUNCHED THE HEALTH INSIGHT PLATFORM, A NEW DATA ANALYTICS AND VISUALIZATION SERVICE THAT USES BEST-IN-CLASS TOOLS TO ADVANCE DATA USE. LAST, PATH INCREASED PARTICIPATION IN HIGH-LEVEL COALITIONS, INCLUDING TRANSFORM HEALTH, THE LANCET/FINANCIAL TIMES JOINT COMMISSION ON GOVERNING HEALTH FUTURES 2030, AND THE DIGITAL CONNECTED CARE COALITION. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRINCIPAL FINANCIAL OFFICER SIGNED THE FORM. FORM 990, PART VI, SECTION B, LINE 12C PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD COMPENSATION COMMITTEE IN 2020. AT THE REQUEST OF THE BOARD, PATH ENGAGED MERCER (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO AND EXECUTIVE TEAM MEMBERS. MERCER USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE MERCER REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE EXECUTIVE TEAM MEMBERS. ADDITIONALLY, MERCER REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE. FORM 990, PART VI, SECTION C, LINE 19 PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. PATH VACCINE SOLUTIONS 2201 WESTLAKE AVENUE SEATTLE WA 98109 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 12A, I PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA ACS PLAZA 4TH FL LENANA RD PO BOX NAIROBI KE EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH KE 501(C)(3) PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 PATH VACCINE SOLUTIONS C 4386562 FMV PATH VACCINE SOLUTIONS B 46272 FMV FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND B 4534968 FMV